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ABSTRACT  
   
Controlled release formulations for local, in vivo drug delivery are of growing interest to 
device manufacturers, research scientists, and clinicians; however, most research 
characterizing controlled release formulations occurs in vitro because the spatial and 
temporal distribution of drug delivery is difficult to measure in vivo. In this work, in vivo 
magnetic resonance imaging (MRI) of local drug delivery is performed to visualize and 
quantify the time resolved distribution of MRI contrast agents. I find it is possible to 
visualize contrast agent distributions in near real time from local delivery vehicles using 
MRI. Three dimensional T1 maps are processed to produce in vivo concentration maps of 
contrast agent for individual animal models. The method for obtaining concentration 
maps is analyzed to estimate errors introduced at various steps in the process. The 
method is used to evaluate different controlled release vehicles, vehicle placement, and 
type of surgical wound in rabbits as a model for antimicrobial delivery to orthopaedic 
infection sites. I are able to see differences between all these factors; however, all images 
show that contrast agent remains fairly local to the wound site and do not distribute to 
tissues far from the implant in therapeutic concentrations. I also produce a mathematical 
model that investigates important mechanisms in the transport of antimicrobials in a 
wound environment. It is determined from both the images and the mathematical model 
that antimicrobial distribution in an orthopaedic wounds is dependent on both diffusive 
and convective mechanisms. Furthermore, I began development of MRI visible 
therapeutic agents to examine active drug distributions. I hypothesize that this work can 
be developed into a non-invasive, patient specific, clinical tool to evaluate the success of 
interventional procedures using local drug delivery vehicles.
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Chapter 1: INTRODUCTION 
 
1.1 Introduction to Local Drug Delivery 
Local drug delivery is increasing in popularity in both research and industry. 
Local drug delivery vehicles can create a high concentration of drug in a specific region, 
while maintaining much lower levels of therapeutic in other areas of the body 
1,2
. This 
can focus treatment to an affected region, which is important in a variety of applications 
such as tumor treatment 
3
, pain management 
4,5
, tissue engineering 
6
, and infection 
management 
7
. Local drug delivery vehicles come in a multitude of formulations and can 
be tailored for a specific function. Broadly local drug delivery vehicles can be 
categorized by their properties such as biodegradable or bioinert, fast or slow releasing, 
and bulk or surface releasing. Fast releasing materials include bioresorbable collagen and 
fibrin gels, which can release their entire load in 24 hours 
8
. The slowest releasing 
vehicles are not penetrated by water, limiting drug release to pores in the vehicle. Pores 
can easily be created by porogens, which remain a solid during material synthesis, but 
then dissolve in the presence of certain solvents, leaving empty space. Polymethyl 
methacrylate (PMMA) is commonly used as a delivery vehicle for antimicrobials in 
orthopaedics and acts under such mechanisms. In antimicrobial loaded PMMA the pores 
are created by the antimicrobials themselves so release is a function of the amount of 
drug loaded 
9
. When low amounts of antimicrobial are loaded in PMMA release might be 
as slow as 3-5% over 1 month
10
. 
 
1.2 Orthopaedic Infection 
  2 
 
1.2.1 Scope of the Problem 
Orthopaedic infections are infections of orthopaedic implants such as artificial 
joints and fracture fixation devices. These infections occur in about 1-2% of primary 
arthroplasties
11,12
. The rate is higher in traumatic wounds, such as in traumatic wounds of 
the spine where the rate of infection is 9.4% 
13
. Once established these infections are 
difficult to cure with 10-23% of patients experiencing recurring infection 
14,15
. There are 
approximately 112,000 cases of orthopaedic infections annually in the US 
16
. Infections 
are devastating to the patient physically often requiring the patient to rely heavily on the 
assistance of caregivers for an extended period of time. Not only are infections physically 
painful, but they place a significant financial burden on patients as well. Each case of 
infection treatment costs $15,000 to $233,000 
16,17
. Darouiche et al. estimated in 2004 
that 1.8 billion dollars were spent annually on orthopaedic infection in the US 
16
. The 
annual cost is likely larger currently as more patients receive arthroplasties every year. 
The number of arthorplasties performed annually is projected to increase by several fold 
over the next 18 years 
18
.  
 
1.2.2 Biofilm Development and Proliferation 
Orthopedic infections are complex problems because they are the result of biofilm 
forming microbes, such as Staphylococcus aureus. The microbes attach to the surface of 
the implant and through quorum sensing begin to establish a communal 
microenvironment, biofilm, when enough bacteria are present 
19
. Biofilms protect against 
the host response system by enveloping  neutrophils with planktonic bacteria ejected 
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from the biofilm 
20
 and deactivating antimicrobial peptides 
21
. Furthermore, biofilm 
residing microbes are much less susceptible to antimicrobials because of multiple 
mechanisms 
22
. First, the biofilms cause a barrier to antimicrobial transport in some cases. 
Microbes, like positively charged gentamicin, can become bound to the negatively 
charged polysaccharide matrix, limiting their ability to penetrate thick biofilm 
22-24
. In 
addition to the biofilm potentially limiting the transport of antimicrobials to the bacteria, 
the microbes themselves are resistant to antimicrobials 
25,26
. The resistance, however, is 
not the product of traditional genetic mutations adopted by the microbes over time 
because bacteria from a dispersed biofilm recover their antimicrobial sensitivity quickly 
22,27,28
. There are several possible methods that could cause bacteria to be less susceptible 
to microbes because of the microenvironment. The microenvironment in biofilm is very 
heterogeneous, supporting multiple variations of the bacteria within the same colony
19
. 
For instance, areas where there are very low transport of nutrients could lead to 
deregulation of the metabolisms of bacteria in those areas. These bacteria would then be 
less susceptible to antimicrobials because they are in a sessile state. Other factors, such as 
pH and osmotic pressure could play a role in bacterial differentiation and hence 
antimicrobial susceptibility as well. These factors lead to antimicrobial sensitivities 100-
1000 times less in biofilm than in planktonic bacteria  
25,26
. When insufficient 
concentrations of antimicrobial are delivered to planktonic bacteria they can even 
propagate the development of biofilms 
29,30
. Since antimicrobial action is time and 
concentration dependent, high concentrations need to persist to be effective. For instance, 
biofilm methacillin-resistant Staphylococcus aureus takes more than 5 days of exposure 
to 2 mg/mL vancomycin to be eradicated 
29
. The levels of antimicrobial required to kill 
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biofilm residing microbes cannot be achieved systemically without causing toxic effects. 
Local drug delivery is required to effectively treat biofilm infections such as those 
present in orthopaedic infections. 
 
1.2.3 Surgical Treatment of Orthopaedic Infection 
Most orthopaedic infections are treated by a two stage surgical revision 
15,31-35
. In 
the first stage the biofilm and implant are removed and the surrounding tissue is debrided. 
The space is then filled with antimicrobial loaded bone cement. The bone cement is left 
for several weeks to treat any biofilm debris remaining in the tissue and planktonic 
bacteria in the muscle
15,33
. The implant cannot be replaced at this time as any bacteria still 
in the patient could reattach to that surface and cause a recurrent infection 
36
. After the 
several week delay the second stage can be performed where the ABLC is removed and 
the implant is replaced. Surgeons aim to cover the entirety of the wound surface as well 
as penetrate into the surrounding muscle with antimicrobial in case the debridement 
wasn't complete or there were planktonic bacteria. 
 
1.2.4 In Vitro Characterization of Orthopaedic Bone Cement 
Antimicrobial loaded bone cement can be bought with low doses of antimicrobial 
from several manufacturers, including Simplex® (Stryker, Kalamazoo, MI), but many 
surgeons mix antimicrobials into cement at the time of surgery. Bone cement is bought as 
a package of polymethyl methacrylate (PMMA) powder that contains benzoyl peroxide 
and  methyl methacrylate (MMA) liquid with N,N-dimethyl-p-toluidine 
37
. When the 
MMA liquid is added to the powder the N,N-dimethyl-p-toluidine reacts with benzoyl 
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peroxide to create free radicals and initiate a free radical polymerization 
37,38
. The MMA 
polymerizes with the PMMA powder and after several minutes forms a hard solid 
37
. 
Before the mixture hardens a surgeon can form the dough into any shape or can use the 
dough to cement an implant in place. Antimicrobials can be added to the powder before 
the addition of the monomer. The antimicrobial powders do not dissolve in the monomer 
so after the cement is dry there is a solid matrix of PMMA with antimicrobial powder 
imbedded throughout. When aqueous fluid, such as that present in the body, contacts the 
antimicrobial, the powder will dissolve and the antimicrobial will elute from the cement 
leaving a pore in the cement where the powder used to be. Aqueous fluid can then invade 
that space and dissolve the next antimicrobial powder it contacts. The process continues 
until the fluid has penetrated all interconnected pores. There are many methods to modify 
the cement formulation to obtain high antimicrobial release, such as the inclusion of other 
inert porogen or fillers to increase the pore interconnectivity 
9
. There is much data for in 
vitro research on antimicrobial loaded bone cement of varying compositions 
9,39-50
. For 
instance, Klekamp et. al. studied the elution of several antimicrobials, vancomycin and 
tobramycin, from  two different bone cements and looked at the compressive strength and 
fatigue life of the cements 
47
. They found that antimicrobials maintain activity after 
elution from cement, both antimicrobials did elute, and although low doses of 
antimicrobial do not significantly affect compressive strength, it does shorten the fatigue 
life of the cement 
47
. Lewis et. al. developed a method to determine the optimum mass 
percent of antibiotics to load in weight baring cement as a function of antimicrobial 
release and compressive strength 
48
. Rasyid et. al studied  adjusting the amount of MMA 
monomer to use in the powder to increase porosity and antimicrobial elution from 
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cements. Other groups have looked at the addition of various fillers or composite 
materials such as Schnieders et al. who used a poly (lactic-co-glycolic acid)/PMMA 
composite to increase antimicrobial release. McLaren et al.  studied the homogeneity of 
hand mixed bone cement compared to commercial formulations and found there is no 
difference between the two. There are over a thousand other studies on various aspects of 
antimicrobial loaded bone cement since its invention in 1970
50
. In vitro experiments 
studying elution of antimicrobials from cement are usually performed in near infinite sink 
condition, where specimens with simple geometries are kept in relatively large volumes 
of well mixed aqueous fluid 
46,47
. This experimental setup allows for calculation of 
various transport properties of the material such as flux, which is surface area and volume 
dependent. By performing these simple experiments researchers can easily compare 
delivery vehicles of various compositions. Furthermore, by using infinite sink conditions 
the greatest possible release can be calculated so the safety of the vehicle can be 
evaluated. These experiments, however, cannot describe how drugs will distribute in 
complex in vivo tissue.  
 For instance, bone is a barrier to antimicrobial transport. The effective diffusion 
coefficient water in bone (Deff=7.8x10
-11
 m
2
/s) 
51
 is much lower than in muscle 
(D=1.38x10
-9
 m
2
/s) 
52
. When antimicrobial loaded cement is in bone there will be an 
accumulation of antimicrobial between the bone and the cement. The accumulation will 
decrease the concentration gradient from between the cement and its environment, the 
driving factor for antimicrobial delivery, and delivery from the cement will decrease. 
Therefore, in vitro testing cannot predict in vivo concentration over time and location. 
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1.2.5 In Vivo Characterization of Orthopaedic Bone Cement 
To gather information on the in vivo behavior there have been some research 
collecting fluid samples and biopsies 
1,2,53-57
. In general concentrations are over 100 times 
higher near the implant than in the blood 
1,53
. Biopsies from Adams et al showed effective 
concentrations were delivered up to 28 days after the surgery 
2
. From that and other 
studies it is confirmed that therapeutic doses can be achieved at a location in vivo 
1,2,53-56
, 
however the biopsy based technique is limited in spatial resolution to the number of 
samples obtained. Furthermore, the biopsy method is time consuming. Several groups 
have studied in vivo patient outcomes to determine treatment efficacy 
7,14,31,58-61
. Dunbar 
et al looked at the patient outcomes using antimicrobial loaded bone cement versus using 
systemic antimicrobials only 
7
. Cierney et al. looked at how patient health effected their 
prognosis 
58
. Walenkamp et al looked at the long term prognosis of patients receiving 
antimicrobial bone cement and assessed its relationship to healing 
59
. Other groups have 
assessed safety of different amounts of loading 
62
. These methods can help develop better 
procedures, but they cannot determine reasons for failure. Furthermore, these methods 
require a large number of replicates a long experimental time to be meaningful, so it is 
unknown if the method is effective until after several years.  
 
1.3 MRI Visualization of Contrast Agents 
In this work, to obtain the comprehensive spatial distribution of drugs eluting 
from local drug delivery vehicles in orthopaedic surgical wounds the distribution of 
contrast agents is imaged using magnetic resonance imaging (MRI).  
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1.3.1 Basic MRI Physics and How Contrast Agents Work 
MRI visualizes the motion of water molecules. When protons are placed in a 
magnetic field their axis tend to align with the direction of the field 
63
. Not only do they 
align with the field, they also process about the axis of the magnetic field at a rate that is 
proportional to the magnetic field strength, called the Larmor frequency 
63
. A radio 
frequency (RF) electromagnetic pulse can be applied at the Larmor frequency, the 
resonant frequency of the protons, and cause the magnetic moments of the protons to 
align so they process together. The net magnetization of a group of protons causes an 
electromagnetic signal that can be detected by a transceiver coil 
64
. If the RF pulse is 
applied at an angle from the main magnetic field it can cause the axis of the protons to tip 
toward the RF pulse while the pulse is being applied. The angle of the RF pulse is 
referred to as flip angle 
64
. After the RF pulse is finished the magnetic moments of the 
processing proton spins begin to misalign or dephase. The time it takes for the magnetic 
moments to dephase is commonly referred to as spin-spin or transverse relaxation time 
and is referred to as T2 time 
63,65
. While the spins are dephasing the tilt of the axis are also 
changing to return back to the starting state of alignment with the main magnetic field. 
The time it takes for the axis to return to their starting state is referred to as spin-lattice or 
longitudinal relaxation time. The longitudinal relaxation time is referred to as the T1 time 
63,65
.  
The magnetic signal of the protons is detected by a transceiver coil in the 
transverse plane. The transceiver acquires signal at a certain time, called the echo time 
(TE), after the RF pulse was emitted . Multiple measurements must be made on a single 
slice to obtain all the spatial information. The time between successive measurements is 
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called the repetition time (TR) 
64
. Different MRI sequences incorporate different flip 
angles, TR, and TE times to emphasis different relativities. T1 weighted images are 
obtained using short TE and TR times. 
MRI contrast agents exhibit paramagnetic or ferromagnetic properties, meaning 
they are able to effect the magnetic field surrounding them. When water molecules are 
near the contrast agents their spins are affected by the magnetic field of the molecule. 
When an RF pulse is applied molecules in contact with the contrast agent return to 
equilibrium faster than they would without the presence of that magnetic field. This 
decreases the observed T1 and T2 relaxation rates. Some of the molecules used as contrast 
agents, such as gadolinium, are toxic in their ionic forms requiring them to be bound by a 
chelator to reduce or eliminate the toxicity 
66
. The effect of a contrast agent is dependent 
on several factors including the number of water molecules it can bind at a time (the 
hydration number) and the length of time water molecules are bound (the exchange rate) 
67
. Contrast agents with high exchange rates and hydration numbers produce a greater 
effect on the MR signal 
67
. The concentration of contrast agent in a certain region is 
proportional to the decrease in T1 or T2 time. The proportionality constant is called the 
relaxivity constant of the contrast agent.  
 
1.3.2 Research of MRI Parameter Effecting Calculation of Contrast Agent Concentration 
There have been many studies that have considered various aspects of the MRI 
contrast/concentration relationship based on in vitro tests. Stanisz et al. studied the 
relationship between contrast relaxivity and macromolecular content, finding that the 
relaxivity of a contrast agent can vary by over 200% when the macromolecular content in 
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a fluid is raised from 0 to 40wt% 
68
. Noordin and colleagues found the influence of ionic 
proteins commonly found in synovial fluid on the relaxivity of Gd based contrast agents 
is minimal at measurable concentrations 
69
. Rohrer et al. studied the relationship between 
relaxivity and magnetic field strength an found that the relaxivity of Gd-DTPA changed 
by 10% between 0.47 and 4.7 T magnets
70
. Fleckenstein et al. found that there was as 
great as 50% variability in normal muscle T1 values based on the exercise state of the 
muscle 
71
. Prantner shows in an in vitro study that without functionalization of MR 
chelates with transmembrane peptides, little contrast agent is intracellularized in 
mammalian cells 
72
. If contrast agent is not intracellularized the effect of differences in 
intracellular environment on observed relaxivity is minimized. Donahue et al. 
73
 and 
Strich et al. 
74
 studied relaxivities of contrast agent in different tissues and found that the 
relaxation of Gd-DTPA in different tissues was not statistically different. 
 
1.3.3 Previous Experiments Calculating Concentration of Contrast Agent in MRI 
Magnetic resonance imaging (MRI) has been used to visualize distribution of 
drugs delivered locally in several clinically relevant applications. Drug delivery from 
catheters in convection enhanced delivery procedures for treatment of glioblastomas has 
been studied by multiple research groups 
75-78
. Sarntinoranont and co-workers have 
studied delivery of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) delivery 
to tumors 
79
, and they calculate concentration of the Gd-DTPA using a method validated 
in an agarose phantom 
80
. Several other groups have calculated concentrations of contrast 
agent in vitro as well 
73,81-84
. However, their methods of quantification are not validated in 
vivo to determine sources of error or to quantify the error likely in their in vivo 
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measurements. Sampson and co-workers also deliver MRI contrast agents to tumors, but 
no quantification of the agent’s concentration is performed 76,77. Krauze et al.78 and Port 
et al. 
85
 imaged liposomal Gd-DTPA delivery, but neither quantified concentration. Fritz-
Hansen et al. calculated bulk concentration of contrast in arterial blood, but was not 
concerned with spatial distribution 
86
. Kim et al. quantified the distribution of drugs 
delivered from an ocular implant using MRI 
87
; however, the function used by Kim et al. 
to convert MR intensity to concentration is similar in shape to a parabola and thus results 
in two valid concentrations for most MR intensity values – one concentration being high 
and the other being low concentration; thus, the user must infer which concentration is 
more likely based on proximity to the depot. 
 
1.4 Transport of Drugs in Physiological Systems 
The change in drug concentration over time is reliant upon 3 factors: the diffusion 
of the drug into or out of the system, the amount of drug leaving or entering the system 
due to bulk fluid flow and the generation or consumption of the drug within the system 
88
. 
The diffusion of a drug is proportional to the concentration gradient. When there is a 
steep concentration gradient, such as when a drug delivery vehicle is placed in a fluid 
containing no drug, the diffusion occurs faster than when the concentration gradient is 
low, such as when the concentration outside of a delivery vehicle is near the 
concentration inside the delivery vehicle. When concentrations in one area are equal to 
concentrations in an adjacent area there will be no diffusive exchange of the molecule 
between those areas. Diffusion is also a function of a physical constant, the diffusion 
coefficient, that describes the inherent properties of the material a molecule is diffusing 
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through. In a dense material, such as bone, the diffusion coefficient of a molecule is 
lower than in a free liquid such as water. Diffusion coefficients are related, among other 
factors, to the size of the molecule diffusing. Large molecules will diffuse more slowly, 
have a lower diffusion coefficient, than smaller molecules. I hypothesize that the contrast 
agent Gd-DTPA is a fairly accurate model for antimicrobials because it has a similar size 
and hence diffusion coefficient (D=4.0 x 10
-10
 m
2
/s) 
89
 to the antibiotics Gentamicin (D= 
2.1 x 10
-10
 m
2
/s)
23
 and Vancomycin (D= 3.6 x 10
-10
 m
2
/s) 
90
 in water.  
 Convection is the movement of molecules due to bulk fluid flow. In convection 
the size of the molecule does not matter in most cases. Small molecules will travel at the 
same speed as large molecules, unless the space the fluid is flowing through has pores 
near the size of the larger molecule. Then the large molecule will be hindered by filtration 
while the small molecule would be unaffected. In this work I will assume the size of all 
molecules is sufficiently small in comparison to the pores of the material that filtration 
effects can be ignored. For aqueous fluid the velocity at which fluid flows is proportional 
to the pressure drop across that length of fluid flow 
88,91
. It is also a function of the 
permeability of the tissue 
91,92
. One source and sink of fluid flow in the muscle is from 
capillaries 
93
. When tissue is damaged leukocytes are recruited to the area and the 
capillaries dilate to facilitate their extravasation, which also allows edematic flow from 
the leaky capillary 
94
. 
The consumption or generation of a molecule for transportation can occur because 
of reaction or because of a mechanism that binds or unbinds the molecule, rendering it 
unavailable to transport. Antimicrobials could be affected by this parameter if they get 
taken into bacterial cells, get taken into the vascular system, or bind to other molecules. 
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1.5 Clinical Importance 
Orthopedic surgeons use ALBC to treat infection, but there is no standard 
guidelines for dose 
31,95
 or cement composition.  The lack of standardization could be a 
result of the methods currently employed to characterize ALBC.  Current in vivo research 
methods rely on multiple local biopsies and histology 
1,2,53
, which are not comprehensive 
and are time consuming.  Achieving concentrations above the minimum inhibitory 
concentration in one small area being biopsied does not guarantee sufficient 
concentrations everywhere in the infected region.  Furthermore, taking multiple painful 
biopsies is not practical for human subjects on a patient specific basis. 
In this work the spatial distribution of drugs over time was visualized using MRI. 
The methods presented here give a comprehensive view of the behavior of contrast 
agents in an orthopaedic wound environment in vivo.  Information provided by in vivo 
research studies and mathematical model could provide surgeons with general 
information on ways to improve local delivery depot dose, placement, and composition. 
Furthermore, this technique could be developed into a clinical tool to evaluate the success 
of interventional therapy on a patient specific basis. A patient could receive a vehicle 
containing therapeutic and contrast agent and be imaged within the first 24 hours after 
surgery to evaluate if there was reasonable coverage of the debrided space. If there is not 
contrast seen covering the debrided area intervention could be performed immediately. 
The imaging method could possibly reduce the amount of time for recovery because the 
patient would not have to show signs of recurrent infection before receiving additional 
intervention. 
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In this work a mathematical model of antimicrobial delivery to orthopaedic 
wounds is also developed. Adjusting parameters in the model could provide a quick, 
economical, and ethically responsible way to engineer better potential clinical solutions 
and guide future in vivo experiments.   
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Chapter 2: VISUALIZATION OF LOCAL DRUG DELIVERY USING MRI 
 
2.1 Introduction 
The incidence of infection in primary arthroplasties is 1-2% 
11
 and 10-23% in 
revision arthroplasties 
14,15
. Infections of joint implants cause a financial and physical 
burden on the patient. Treatment often requires multiple surgeries. A major complicating 
factor in orthopedic infection is the development of biofilm. The minimum bactericidal 
concentration (MBC) for bacteria in biofilm is much higher (100-1000x minimum 
inhibitory concentration) than for planktonic bacteria
26,96
. Antimicrobials of these 
concentrations cannot be achieved systemically without severe toxicity. Clinically, 
acrylic bone cement and CaSO4 are commonly used to deliver antimicrobials, although 
other vehicles, including collagen, have been investigated. These vehicles have a variety 
of release rates ranging from 100% over 24 hours for collagen 
8
 to 3-5% over 1 month for 
low-porosity bone cement 
10
. The use of antimicrobial loaded bone cement (ALBC) 
results in high local concentration of antimicrobials and low systemic levels 
1,2
. There is 
an extensive history of in vitro studies of antimicrobial delivery from ABLC 
2,7,11,14,15,46,95,97,98
; however, little is known about the concentration and spatial distribution 
over time in vivo. Current in vivo methods often involve collection of the fluid 
surrounding an implant and serum at various times to obtain a time resolved elution curve 
1,2
. Sometimes tissue segments near the implant are sampled at conclusion of the 
experiment to show some spatial distribution of the drug 
2
. The major limitation of 
previous methods is they are time consuming and spatial distribution is limited to the 
number of biopsies. An ideal method for studying ALBC would give the spatial 
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distribution of antimicrobial concentrations as a function of time. This information could 
assist surgeons in optimizing the dose of antimicrobials and porogen in ALBC, mixing 
methods, surgical placement, and treatment durations, potentially leading to improved 
efficacy for prophylaxis and treatment of periprosthetic infections.  
 The most practical method for acquiring information on spatial distribution of 
antimicrobials as a function of time is through imaging. Drug distribution over time has 
been studied before using imaging, most prevalently in glioma research. Several groups 
have studied delivery of contrast agents to the brain 
75,76
. The imaging research has led to 
some successful modeling techniques for optimum catheter placement during 
neurosurgery 
77
. Other groups have shown it possible to determine actual concentrations 
of contrast agents from MRI images 
73,81-84
. 
This research was conducted as a collaboration between Morgan Giers, Chris 
Estes, Alex McLaren, Michael Caplan and Ryan McLemore. These data are published in 
the journal Clinical Orthopaedics and Related Research 
99
. Specific contributions of each 
team member are stated in the corresponding sections in the methods; however it should 
be additionally noted that all team members participated in analyzing and interpreting the 
data. 
The research questions for this study are: is in vivo distribution of locally 
delivered Gd-DTPA visible on MRI? Is in vivo distribution of locally delivered Gd-
DTPA affected by the anatomic delivery site? Is in vivo distribution of locally delivered 
Gd-DTPA affected by the in vitro release rate from the delivery vehicle? 
 
2.2 Methods 
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Twenty-four local delivery depots were imaged in nine rabbits using three 
delivery sites (intraoseous canal, quadriceps, hamstrings). The left legs received an 
intraoseous rod of a control formulation or loaded with Gd-DTPA in intermediate-
porosity or high-porosity (all in triplicate). The right legs received an intramuscular rod 
of a control formulation or loaded with Gd-DTPA in intermediate-porosity or high-
porosity (all in triplicate); six of the nine rabbits also received a collagen injection either 
with or without Gd-DTPA (each in triplicate).  Gd-DTPA distribution was imaged in 
rabbits after local delivery. Images were assessed for area of contrast distribution as 
visible on MRI. Images were also analyzed for area during an interobserver reliability 
study of a subset of images by blinded reviewers (Fig 2.1). 
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Figure 2.1: A diagram of the experimental setup is shown. 
 
2.2.1 Delivery Vehicle Fabrication 
Diethylenetriaminepentaacetic acid gadolinium (III) hydrate (Gd-DTPA) (Sigma-
Aldrich, St Louis, MO, USA), a water soluble organic chelator loaded with gadolinium, 
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was used as a surrogate for gentamicin sulfate, a hydrophilic antimicrobial commonly 
used in depot delivery to treat orthopaedic infection. These two compounds have similar 
molecular size and solubility and therefore are expected to have similar transport 
properties (Table 2.1) 
23,89
.  
Two types of delivery vehicles were used, collagen and polymethyl methacrylate 
bone cement (PMMA). To prepare the collagen vehicle, Gd-DTPA (Magnavist, Sigma-
Aldrich, St Louis, MO, USA) in 150 mM phosphate buffered saline was mixed with 17 
wt% porcine collagen (Sigma-Aldrich). The solution was heated to 60
o
 C to dissolve the 
collagen and produce a 100 mM Gd-DTPA gel.  
Five types of PMMA delivery vehicles were formulated by Morgan Giers and 
Ryan McLemore. All PMMA orthopaedic bone cement was from Stryker (Simplex P 
bone cement; Stryker, Kalamazoo, MI, USA). All xylitol (Xlear, Orem, UT, USA) used 
was sieved using ASTM E-11 sieves to include only 250-425 µm particle sizes. The 
implant types are as follows: 
(1) The control vehicles for both the intraoseous rods and intramuscular 
rods were made using the manufacturer's instructions (67wt% PMMA and 
33wt% MMA).  
(2) The high dose intraoseous delivery vehicle implants were made with 
1.4wt% Gd-DTPA, 12.9wt% xylitol, a particulate porogen used to 
increase release rate and amount, and 85.7wt% PMMA and polymerized 
MMA. 
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(3) The intermediate dose intraoseous delivery vehicle implants were 
made with 1.4wt% Gd-DTPA, 6.2% xylitol and 92.4wt% PMMA and 
polymerized MMA. 
 (4) The high dose intramuscular delivery vehicle implants were made 
with 2.9wt% Gd-DTPA, 11.4wt% xylitol, and 85.7wt% PMMA and 
polymerized MMA. 
(5) The intermediate dose intramuscular delivery vehicle implants were 
made with 2.9wt% Gd-DTPA, 4.7wt% xylitol, and 92.4wt% PMMA and 
polymerized MMA. 
Doses were selected to be analogous with prophylactic doses of antimicrobial 
used in antibiotic loaded bone cement (ALBC) for fixation. Cement was formed into 9 
cm long by 4 mm in diameter rods using 14 Fr. red rubber catheters (Covidien, 
Mansfield, MA, USA).  
Table 2.1: Comparison of transport properties of antimicrobial and contrast agent. 
 
 
2.2.2 Surgical Procedure 
 Vehicles were implanted by orthopaedic surgeons Alex McLaren and Chris Estes 
either intramuscularly in the thigh or in the intraoseous canal of 9 female New Zealand 
White Rabbits, each 2.5 kg. Animals were sedated with ketamine (35 mg/kg), xylazine (5 
mg/kg), and butrophanol (0.1 mg/kg) prior to surgery, and anesthesia was maintained on 
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2% isoflurane. Anesthesia was given and monitored by veterinary staff of Barrow 
Neurological Institute. A water blanket was used to maintain the rabbit's temperature at 
37
o
C. 
Two types of rod placements were utilized: an intraoseous rod in the femur (IOR) 
and an intramuscular rod (IMR). To place a IOR in the left leg a 0.62 Kirschner wire was 
introduced into the femoral canal in a retrograde fashion through an entry point in the 
intercondylar notch. The Kirschner wire was removed and the canal was dilated to 4 mm 
using drill bits. A (PMMA) rod with composition 1-3 was then placed in the canal.  
The right leg received an IMR, a PMMA rod with composition 1 or 4-5 placed 
intramuscularly in the quadriceps through a 5mm incision made 1-2cm proximal to the 
patella. Finally, an intramuscular injection of collagen (0.2mL) was placed in the 
hamstrings using a 20 G needle.  
 
2.2.3 Image Acquisition 
 Imaging protocol was developed and performed by Qingwei Lui and Gregory 
Turner on a 7T MRI (Bruker Biospin; Billerica, MA, USA) using a rabbit coil. A fat-
suppressed T1 weighted RARE (rapid acquisition with relaxation enhancement) scan was 
used with repetition times (TR)= 1463,2000,3000,5000 ms (TE=9 ms). The region of 
interest included 42 equally spaced planes aligned along the long axis of the femur, 
stretching from the knee to the pelvis. Resolution was 0.3 mm x 0.3mm x 2.0 mm. A 
control image was taken of each animal prior to surgery. Total scan time was 
approximately 14 minutes per series. Each series of RARE images were used to construct 
a T1 map through Bruker® software solving the Bloch Equation for T1 given various 
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intensities at various TR (Fig 2.2) 
63
. Animals were imaged for 6 hours at 15 minute 
intervals, and each set of RARE images were used to construct a T1 map. T1 maps were 
compared over both time and space for each subject to determine release profiles of 
gadolinium from local delivery devices. 
 
Figure 2.2: Multiple RARE scans of the same slice are assembled into a single T1 map. 
 
2.2.4 Euthanasia 
Animals were euthanized at the close of experimentation. All procedures were 
approved by the Institutional Animal Care and Use Committee. National Institutes of 
Health guidelines for the care and use of laboratory animals were observed (Publication 
85-23, revised 1985). 
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2.2.5 Interobserver Correlation 
To determine interobserver reliability, three blinded observers (Jeffery Albigaard, 
James Fraser, Ryan Miller) were asked to review a subset of the images generated in this 
experiment. The observers were junior orthopaedic residents who were familiar with MRI 
but not familiar with the images generated in this project. Chris Estes trained all three 
observers by describing the project and demonstrating the technique to outline the area of 
visualized contrast on three sample images. The observers were then asked to outline the 
perimeter of the area where they visualized Gd-DTPA on 41 images prepared by Morgan 
Giers using MATLAB (Mathworks, Natick, MA, USA). The 41 images included three 
representative images from both PMMA and from collagen across the 6-hour period plus 
controls reviewed in random order. Interobserver reliability was determined by 
calculating interclass correlation coefficient (ICC) between all pairs of observers 
100-102
. 
Bland-Altman plots were constructed and it was determined the interobserver reliability 
did not vary based on the average area. 
 
2.2.6 Statistics 
The effect of different in vitro release rates of the vehicle on distribution of Gd-
DTPA was compared using quantitative data from the interobserver analysis by 
comparing distribution area over several time points. As a result of the inability to 
distinguish Gd-DTPA in collagen from Gd-DTPA in tissue, distribution area in this study 
is not an ideal metric for comparison of vehicles. The rate of change of area was 
calculated and normalized to the first postinjection image for each vehicle to determine if 
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distribution of delivered Gd-DTPA was affected by delivery vehicle. The rates of change 
between vehicles were compared using regression (α = 0.05). Statistical analysis was 
performed by Morgan Giers and Ryan McLemore using Minitab 15 (Minitab Inc., State 
College, PA, USA) to construct Bland-Altman plots and check normality of data, 
MATLAB 7.9 (Mathworks) to calculate interobserver reliability coefficients, and Excel 
(Microsoft, Redmond, WA, USA) to perform t-Tests. All data used in t-Tests were 
confirmed to have a normal distribution through examination of the histogram of 
residuals and the normal probability plot.  
 
2.3 Results 
 
2.3.1 Is In Vivo Distribution of Locally Delivered Gd-DTPA Visible on MRI? 
Contrast agent shortens the T1 values and appears dark on the T1 map. The control 
rods, containing no Gd-DTPA, show no shortening effect outside of the rod, indicating 
drug release is not seen. Control collagen is indistinguishable from the surrounding 
muscle on the T1 maps. Gd-DTPA is visible spreading radially from all vehicles 
containing contrast. The visible area of the implant or implant and contrast as assessed 
during the interobserver correlation study was 27.5 ± 21.5 mm
2
 for the rods with Gd-
DTPA and 10.5 ± 11.2 mm
2 
for rods without contrast (p<0.001). 
All combinations of pairs of blinded observers produced an average ICC of 0.95 
(range, 0.92–0.96). 
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2.3.2 Is In Vivo Distribution of Locally Delivered Gd-DTPA Affected by the Anatomic 
Delivery Site? 
The spatial distribution differs between the two different rod placements, IMR 
and IOR. The contrast from the IOR remained inside the canal (Fig 2.3). The contrast 
from the IMR penetrated muscle until it approached an intermuscular tissue plane, where 
it then spread along the plane (Fig 2.4). Contrast was not observed to penetrate adjacent 
muscles. 
 
2.3.3 Is In Vivo Distribution of Locally Delivered Gd-DTPA Affected by the In Vitro 
Release Rate from the Delivery Vehicle? 
There is a visible difference between the distribution rates of the collagen 
compared to the bone cement. The area of the contrast from collagen decreased between 
1 hour and 4 hours (p=0.007) (Fig 2.5), while the area of contrast from the PMMA rods 
did not change significantly over this time frame (p=0.417). The difference between the 
low and high dose bone cement formulations in the intraoseous canal is not apparent. 
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Figure 2.3: Intraoseous Gd-DTPA PMMA rods. (a) Control, no Gd-DTPA; and (b) 
intermediate dose Gd-DTPA is shown. Images are cross-sections perpendicular to the 
femur. The location of the implant is shown with a circle. The areas of low signal (white 
arrows) indicate drug release. (b1-3) show an increasing area of Gd-DTPA progressing 
with time. Images are from a similar location in the midthigh for both the (a) control and 
the (b) intermediate dose Gd-DTPA. The image series (a1–3) and (b1–3) are the same 
slice for the respective delivery site and animal at progressive time intervals to show 
change over time. 
 
 
Figure 2.4: Intramuscular PMMA Gd-DTPA with (a) control, no Gd-DTPA and (b) high 
dose Gd-DTPA is shown. Images are cross-sections perpendicular to the femur. The 
location of the implant is shown with a white circle. Low signal adjacent to the rod (white 
arrows) indicates drug release. It is possible that the bright signal surrounding the contrast 
is related to progressive edema secondary to the trauma of inserting the rod. (b1-3) show 
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increasing area of Gd-DTPA progression with time. Images are from a similar location in 
the midthigh for both the (a) control and the (b) high dose Gd-DTPA. The image series 
(a1–3) and (b1–3) are the same slice for the respective delivery site and animal at 
progressive time intervals to show change over time. 
 
 
Figure 2.5: Images of collagen Gd-DTPA injections over 6 hours are shown. (a) No 
contrast and (b) 100mM Gd-DTPA. Images are cross-sections perpendicular to the femur 
from a similar location in the midthigh for both the (a) control and the (b) 100 mM Gd-
DTPA. The image series (a1-3) and (b1-3) are the same slice for the respective delivery 
site and animal at progressive time intervals to show change over time. Arrows indicate 
released Gd-DTPA. (b1-3) show decreasing area of Gd-DTPA progression with time. 
 
2.4 Discussion 
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This study was performed to answer the questions: is in vivo distribution of 
locally delivered Gd-DTPA visible on MRI? Is in vivo distribution of locally delivered 
Gd-DTPA affected by the anatomic delivery site? Is in vivo distribution of locally 
delivered Gd-DTPA affected by the in vitro release rate from the delivery vehicle? All of 
these questions have been satisfied with an answer.  
 
Table 2.2: Relevant Literature 
Study Use of MRI Depot material 
Depot 
placement 
Adams et al.
2
 Not used 
bone cement                            
Cefazolin, ciprofloxacin, 
clindamycin Canine tibia 
Astary et al.
75
  
Effectiveness 
of brain 
injection 
Local drug infusion                         
Gd-DTPA-albumin 
Rat 
hippocampus 
Owen et al.
103
 Not used 
bone cement                       
Tetracycline Rabbit femur 
Nelson et 
al.
104
 Not used 
fatty acid dimer-sevacic acid 
bead Gentamicin Rabbit radius 
 
There are several limitations of this study. First, this study was performed over a 6 
hour period, a short timeframe compared to the expected duration of delivery from 
ABLC. The short timeframe could affect the ability to see statistically significant changes 
in drug distribution over time from delivery vehicles with slow release rates, such as the 
ABLC; however, since collagen has a faster release rate a 6 hour duration is sufficient to 
see changes in its distribution. In the future  Morgan Giers, Chris Estes, Alex McLaren, 
Michael Caplan and Ryan McLemore plan to extend the timeframe of this study, but for 
the purposes of this pilot data 6 hours allowed us to draw meaningful conclusions about 
scan parameters and qualitative information about distribution patterns. Second, 
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conclusion were drawn by looking at T1 values, but concentrations of contrast in the 
tissue were not calculated. There is literature available where concentrations of contrast 
agent were able to be calculated from T1 values, but these occur mostly in vitro. There are 
several challenges associated with in vivo calculation of contrast concentration. Contrast 
concentration calculation is normally performed using a pre-contrast and post contrast per 
pixel T1 value, but since the rabbit must be removed from the coil to perform the surgery 
it is difficult to properly align these two images. I continue to develop techniques to 
resolve this image processing challenge. Third, Gd-DTPA is only a surrogate for an 
antimicrobial and has no actual antimicrobial properties. Gd-DTPA was chosen for its 
similar transport properties to gentamicin, but also for the several logistical simplicities 
including: availability as an FDA approved drug, low cost, and available literature. 
Complex chemistry must be performed to transfigure any antimicrobial into an MRI 
visible molecule. Such chemistry is currently being performed by this group. Fourth, 
although Alex McLaren and Chris Estes attempted to keep the surgical procedures 
consistent, slight differences in the surgery and anatomy of the animal could be 
responsible for some of the distribution behavior. Although animal to animal variance 
can reduce statistical significance, it also is a more realistic model of the clinical use of in 
vivo drug delivery. Fifth, local drug delivery is volumetric and should be analyzed for the 
entire implant, where here only a subset of the images were analyzed. Finally, this study 
was performed in healthy tissue. The transport properties in that local environment could 
be effected by the presence of biofilm from an infection. 
The data gathered show definitive trends. The control showed no change with 
time, as expected. The only difference before and after implantation was the presence of 
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the implant, which appears dark as it has no water. The dark spots visible around depot 
devices in all other images of Gd-DTPA containing implants are dynamic over time and 
show that it is possible to view drug delivery using MRI. Furthermore, the high 
correlation of the areas circled by non-expert blinded reviewers show regions of contrast 
can be consistently and reliably identified. From published data on MRI contrast 
sensitivity visible contrast is estimated to have concentrations larger than 100 µg/mL 
84
. 
From the estimated sensitivity this data would appear fairly consistent with tissue 
delivery studies of antimicrobials performed by Adams et al. 
2
, Nelson et al. 
104
, and 
Owen et al. 
103
 The data from this group (Morgan Giers, Chris Estes, Alex McLaren, 
Michael Caplan and Ryan McLemore) showing dynamic changes over time make it 
consistent with the studies by Raghavan et al. and Astary et al. who studied MRI contrast 
infusion in the brain over time 
75,76
.  
There were differences between the behavior of the cement rods in the two 
different locations. The contrast delivered to the intraoseous canals remained there, and 
the contrast delivered to the muscle showed a preference for moving along tissue planes. 
These results have not previously been reported by other groups. 
Distribution is effected by delivery vehicle release rate. Collagen releases most of 
its load in 24 hours 
8
, but bone cement release can last 28 days or more 
2
. In elution 
studies PMMA and collagen show similar release profiles where there is an initial burst 
release followed by a period of decline. In a four hour timeframe a change over time for 
the ABLC release was not seen, but a change in distribution area for the collagen vehicle 
was seen. The difference in rate of change in area for the two different vehicles indicated 
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that this method can provide information on distribution as a function of vehicle release 
rate. 
 
2.5 Conclusions 
In conclusion, MRI can be used to view antimicrobial surrogate distribution from 
orthopedic implants. Furthermore, spatial and time dependent distribution can be 
determined. There was a difference seen between depot material and placement. This 
imaging process could serve as a noninvasive and efficient method for studying drug 
delivery from depot devices.  
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Chapter 3: SPATIOTEMPORTAL QUANTIFICATION OF LOCAL DRUG 
DELIVERY USING MRI 
 
3.1 Introduction 
Controlled release formulations for local drug delivery are of growing interest to 
device manufacturers, research scientists, and clinicians. There are many current and 
potential applications for controlled release devices, including cancer treatment 
3
, pain 
management 
4,5
, tissue engineering 
6
, and infection treatment 
7
. For decades orthopaedic 
infection management has relied on the use of antimicrobials delivered from bone cement 
at the infection site 
14
. There are an estimated 112,000 total orthopaedic infections of 
arthroplasties and fracture-fixation devices per year 
16
, and this number is expected to 
increase as the projected number of arthroplasties will likely increase by several fold over 
the next 18 years 
18
. Approximately $1.8 billion is spent annually on increased medical 
costs due to orthopaedic infection of total joint arthroplasties in the US 
16
. Orthopaedic 
implant infections result from common human skin microbes, such as Staphylococcus 
epidermidis and Staphylococcus aureus, and are often complicated by biofilm formation. 
Biofilm residing microbes are not only protected by transport limiting polysaccharide 
matrix, but are more resistant to antimicrobials 
22
. Antimicrobial concentration of 100-
1000 times the usual minimum inhibitory concentration (MIC) used to treat planktonic 
microbes are required to treat infections with biofilm effectively 
25,26
. Intravenous 
delivery to achieve these antimicrobial levels will cause serious systemic toxicity for 
most of the antimicrobials used to treat implant infections. Local drug delivery at the site 
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of orthopaedic infection is used to achieve effective concentration of antimicrobial 
without systemic toxicity. 
Even though antimicrobial loaded bone cement (ALBC) is intended for in vivo 
use, most release studies of antimicrobials from ALBC have been performed in vitro. For 
instance, researchers commonly characterize drug elution profiles from controlled release 
formulations by placing samples of known geometry under near infinite sink conditions, 
such as a large volume of frequently exchanged fluid 
46,47
. While release studies give 
valuable information necessary for directly comparing different controlled release 
formulations, it does not represent how or where the drugs will distribute when the device 
is implanted. Infinite sink conditions produce the greatest possible release of drug which 
represents the potential release capability not the actual elution profiles likely to be 
achieved in vivo, where mass transport resistances from the surrounding tissue are likely 
to decrease the rate of release. In vivo studies have been performed 
1,2,53,58
, but none 
provide comprehensive information on the spatial and temporal distribution of drug 
delivery. In vivo tests frequently focus on efficacy, such as infection control 
58
, but do not 
provide detail regarding how the antimicrobial is distributed because this is difficult, 
expensive, and time consuming to measure. In vivo animal experiments that do consider 
spatial distribution of antimicrobial commonly utilize tissue biopsies near implants and 
collect fluids, such as seroma, blood, and urine 
1,2,53
. These techniques are time 
consuming to analyze, not comprehensive (e.g., resolution is low due to limited number 
of samples), and of limited clinical applicability to humans due to their invasiveness and 
requirements for multiple sampling. 
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Magnetic resonance imaging (MRI) has been used to visualize distribution of 
drugs delivered locally in several clinically relevant applications. Drug delivery from 
catheters in convection enhanced delivery procedures for treatment of glioblastomas has 
been studied by multiple research groups 
75-78
. Sarntinoranont and co-workers have 
studied delivery of gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) to tumors 
79
, and they calculate concentration of the Gd-DTPA using a method validated in an 
agarose phantom 
80
. Several other groups have calculated concentrations of contrast agent 
in vitro as well 
73,81-84
. However, their methods of quantification are not validated in vivo 
to determine sources of error or to quantify the error likely in their in vivo measurements. 
Sampson and co-workers also deliver MRI contrast agents to tumors, but no 
quantification of the agent’s concentration is performed 76,77. Krauze et al.78 and Port et 
al. 
85
 imaged liposomal Gd-DTPA delivery, but neither quantified concentration. Kim et 
al. quantified the distribution of drugs delivered from an ocular implant using MRI 
87
; 
however, the function used by Kim et al. to convert MR intensity to concentration is 
similar in shape to a parabola and thus results in two valid concentrations for most MR 
intensity values – one concentration being high and the other being low concentration; 
thus, the user must infer which concentration is more likely based on proximity to the 
depot.  
In this work, in vivo MR imaging of local delivery of Gd-DTPA from polymethyl 
methacrylate (PMMA) bone cement was converted to Gd-DTPA concentration to provide 
time-resolved maps of Gd-DTPA concentration. The contrast agent, Gd-DTPA, was 
chosen because of its similar solubility and diffusion coefficient (4.0x10
-6 
cm
2
/sec) 
89
 to 
the antimicrobials Vancomycin (3.64x10
-6 
cm
2
/sec)
90
 and Gentamicin (2.08x10
-6 
cm
2
/sec) 
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23
, which are common choices to treat infected orthopaedic implants. This chapter 
presents a detailed protocol for performing this method on an animal model. Further, 
sources of error are discussed and quantified when possible. Finally, methods of image 
volume registration are demonstrated and compared to the method proposed here 
(average value of pre-contrast T1 applied to all voxels). 
This research was conducted as a collaboration between Morgan Giers, Alex 
McLaren, Jonathan Plasencia, David Frakes, Ryan McLemore, and Michael Caplan. 
These data are accepted for publication in the journal Computational and Mathematical 
Methods in Medicine 
105
. Specific contributions of each team member are stated in the 
corresponding sections in the methods; however it should be additionally noted that all 
team members participated in analyzing and interpreting the data. 
 
3.2 Methods 
 
3.2.1 Delivery Vehicle Fabrication 
Delivery vehicles were prepared by Morgan Giers and Ryan McLemore. PMMA 
bone cement was formed using Simplex P
®
 bone cement (Stryker, Kalamazoo, MI, 
USA). Control implants, with no contrast agent, were made according to the 
manufacturer’s instructions. Experimental implants were made identically with the 
addition of either (a) an additional 2.1vol% (2.9wt%) Gd-DTPA, an MRI contrast agent, 
8.8vol% (11.4wt%) xylitol, a particulate porogen used to increase release rate and 
amount, and 89.1vol% (85.7wt%) PMMA and polymerized MMA or (b) an additional 
1.1vol% (1.4wt%) Gd-DTPA, 9.9vol% (12.9wt%) xylitol, and 89vol% (85.7wt%) 
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PMMA and polymerized MMA. Implants of all compositions were formed into 3 mm 
diameter x 7 cm long rods using a red rubber catheter (Covidien, Mansfield, MA,USA) as 
mold. 
 
3.2.2 Surgical Procedure 
All procedures were compliant with the National institute of Health guidelines for 
the care and use of laboratory animals and approved by the Institutional Animal Care and 
Use Committee. All studies were performed using New Zealand White rabbits.  
In the first set of procedures, cylindrical shaped implants were placed by Alex 
McLaren and Chris Estes in either muscle, intramuscular rod (IMR) or the intramedullary 
canal of the femur, intraoseous rod (IOR). The right quadriceps of each animal received 
an IMR of either the experimental (2.1vol% Gd-DTPA,8.8vol% xylitol, 89.1vol% 
PMMA and polymerized MMA) (n=3) or control (no Gd-DTPA, no xylitol)(n=3) cement 
composition. The left femur of each animal received an IOR of either the experimental 
(1.1vol% Gd-DTPA, 9.9% xylitol, 89vol% PMMA and polymerized MMA) (n=3) or 
control (n=3) composition. These procedures are described in previous work by these 
authors 
99
. 
In a second set of procedures (performed by Alex McLaren and Kenneth 
Schmidt), either a partial thickness of muscle (PTM) or a full thickness of muscle and 
bone (FTMB) was removed and replaced with bone cement. For the FTMB wound, 
muscle tissue was removed and a femoral window was created. The femur and muscle 
received cement containing Gd-DTPA. Only the skin was closed over the wound using 
suture. In the PTM model, muscle was removed, the dead space was filled with cement 
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containing contrast. The muscle, fascia lata, and skin were closed with suture. These 
procedures are described more thoroughly in other work by these authors 
106
. 
 
3.2.5 Image Acquisition 
A series of T1-weighted rapid acquisition with relaxation enhancement (RARE) 
scans were taken by Gregory Turner and Qingwei Lui at repetition times (TR) of 1463, 
2000, 3000, and 5000 ms (RARE=2 and no averages) on a Bruker Biospin
®
 7-T MRI 
(Bruker Biospin, Billerica, MA, USA) every 15 minutes for 4-6 hours (Fig 3.1a). A 15-
cm quadrature transceiver coil was used. Flip angle of the RF pulse was calibrated by the 
Bruker software before each scan. The images did not have ghosting artifacts, indicating 
the calibration was successful. The images were taken with coronal slices from knee to 
hip, 42 slices total (field of view=12 cm), with a voxel size of 0.3mm x 0.3mm x 2mm, 
where the slice thickness was 2 mm, and a matrix size of 256x256x42. The temporal 
resolution was 14 minutes. The series of T1-weighted images at different TR was used by 
the Bruker software to construct a longitudinal relaxation time, T1, map based on the 
solution to the Bloch equation: 
            
  
  
                                          (eq3.1a) 
      
  
  
                                                
(eq3.1b) 
where S was the signal intensity, TR was repetition time (time between RF pulses), T1 
was the longitudinal relaxation time, and S0 was defined in equation 3.1b where k was the 
proportionality constant based on instrument factors,  was the spin density, TE was the 
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echo time, and T2 was the transverse relaxation time 
63
. The estimated error of the T1 map 
construction process was calculated by taking the residuals of the curve fitting process for 
1 pixel. In a T1-weighted image, contrast, and fat appeared bright; whereas, cement and 
bone appeared dark as seen in figure 3.1a. In the T1 map, fat appeared bright; whereas, 
contrast, bone, and cement appeared dark as seen in figure 3.1b. 
 
3.2.5 Image Processing 
All image processing was performed by Morgan Giers (with the exception of the 
registrations discussed later in this section) with significant input from David Frakes, 
Michael Caplan, and Ryan McLemore. The T1 maps were imported into MATLAB
® 
(Mathworks, Natick, MA, USA). In MATLAB
  
the images were treated with a noise 
reducing filter. The filter acts only within an image slice and changes a pixel to the 
median value based on the pixel and its 4 nearest neighbors' original values.  The 4 
nearest neighbors are the pixels directly above, below and to either side of the central 
pixel. The filter is applied uniformly to all pixels in the image slices, without regard for 
location in the image. The filtering results are shown in figure 3.1c. Subsequently, a 
binary mask of the leg area was made by morphologically opening the filtered T1-
weighted image slice, applying a binary threshold, filling holes, and removing groupings 
of pixels less than 100, the morphologically closing the image slice. The binary mask of 
the leg area was used to mask noise from outside of the legs in the T1 map (Fig 3.1c). A 
histogram of the cleaned image was then calculated. The histogram was made symmetric 
by replicating the portion of the histogram with T1 values greater than the peak value. 
The symmetry of the histogram removed pixels containing contrast, cement, and air 
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outside of the legs and create a Gaussian distribution. Then the average value and 
standard deviation from the symmetric histogram was calculated. After the average 
histogram value was obtained both the T1-weighted and T1 map image slices were 
exported from MATLAB as a series of TIFF files. The TIFF images were imported into 
Mimics
®
 (Materialise, Leuven, Belgium), where the T1 map was thresholded to a value of 
one standard deviation below the average value of the symmetrical histogram. The 
threshold level was determined to align with segmentations performed by a group of 
experts. All pixels within the muscle tissue of the leg were segmented from the 
thresholded region. Then, all the pixels connected to the implant in the muscle tissue 
region were segmented. This segmentation gave a region of all the pixels connected to 
the implant within the muscle of the leg, which included the cement implant and contrast 
agent  After muscle implants and contrast were segmented several steps were performed 
to segment contrast within the intramedullary canal of the femur. Both the intramedullary 
canals of the femur from the same rabbit were segmented from the T1-weighted image 
volume using a semiautomatic gradient flow detection algorithm, which is similar to the 
method shown by Karasev et al.
107
. Only the fat and marrow within the intramedullary 
canal was included in the segmented region, excluding the cortex of the femur. The mask 
of the segmented region from the femur without contrast was imported back into 
MATLAB, where a symmetric histogram was created for the intramedullary space. The 
histogram was made symmetric to remove pixels from outside the masked region, which 
were given a value of 0. The average and standard deviation of the symmetric histogram 
was calculated. In Mimics the masked intramedullary space of the femur containing an 
implant and contrast agent was thresholded to one standard deviation below the average 
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value of the histogram of the intramedullary canal containing no contrast from the same 
rabbit. All pixels connected to the cement implant within this thresholded region were 
segmented. Additionally, the exterior of the cortex of the femur was segmented using a 
semiautomatic gradient flow detection algorithm in Mimics and manual correction. The 
femurs were then processed with a 3D object smoothing function and included as an 
anatomical reference in 3D images. The legs were also segmented for an anatomical 
reference using thresholding, manual correction, and 3D object smoothing. The 
segmented femur, legs, and contrast were plotted together as 3D objects using Mimics as 
shown in figure 3.1h. The segmented regions of contrast and cement were exported as a 
series of mask images in a bitmap format. The bitmaps were imported back into 
MATLAB where they were transformed into a binary image mask. The binary image 
mask was multiplied by the T1 map to give a map in only the area of contrast (Fig 3.1d). 
The contrast region was transformed into a concentration map (Fig 3.1e & 3.1f) using: 
 
  
 
 
    
                                       (eq3.2)
68,80,81
 
where T1,0 is a pre-contrast T1 map value and T1 is the post-contrast T1 map value. For 
equation 3.2 the average symmetrical histogram values per tissue (muscle or 
intramedullary canal) within a single rabbit was used for T1,0. The value 0.0038 mM
-1
s
-1
 
was used as the value for r1
70
. The relaxivity value was chosen because it is near many 
reported values for relativity measurements for Gd-DTPA in tissues  at 3-7T. Rohrer et 
al. obtained this relaxivity value for Gd-DTPA relaxation in serum at 4.7T 
70
. The 
concentration map was superimposed onto a T1-weighted image to provide the 
anatomical details as shown in figure 3.1g.   
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Figure 3.1: (a) T1-weighted image, (b) ROI of T1-weighted image (c) Original T1 Map, 
(d) Filtered and masked T1 map, (e) T1,0 calculated from the average of the symmetric 
histogram of (d), (f) segmented region of contrast, (g) 1/T1-1/T1,0 or 1/(d)-1/(e), (h)region 
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where T1=na, (i) concentration map where the scale is in mM, (j) concentration map 
superimposed onto T1-weighted image, (k) 3D reconstruction from Mimics. 
  
To avoid spatially registering a pre-contrast and post-contrast image volume, the 
assumption of isotropy of the T1,0 value within a certain tissue type was made. To 
evaluate if a single value for different animals could be used, histograms of 5 pre-contrast 
rabbits (rabbit #1,8,9,15,18 in the series) were composed. The average value of these 
histograms was used as the T1,0 value for all images. The standard deviation of the 
compiled 5 histograms was also calculated. Concentrations were plotted for different T1 
values using the mean T1,0 value with error bars, T1,0 one standard deviation greater than 
and less than the mean T1,0. The standard deviation was chosen instead of a 95% 
confidence interval because the standard deviation was greater than the confidence 
interval and would show greater potential error. To evaluate if one value could be used 
for multiple tissue types, histograms were calculated for the femur and the muscle 
separately. 
Next the isotropic T1,0  technique was compared/contrasted with using T1 values 
from an image in which no contrast is present. This requires that the image volumes with 
no contrast be spatially registered to the image volumes with contrast present. Such a 
registration was completed for one image set. First a 3D rigid body affine registration 
was performed by Jonathan Plasencia in which matching points on the femur in pre-
contrast and post contrast images were chosen by Morgan Giers. A transformation matrix 
was created by Jonathan Plasencia and optimized using singular value decomposition 
similar to a method outlined by Eggert et al. 
108
. The pre-contrast image volume was 
  43 
transformed using a 3D linear interpolation algorithm, which used Delaunay triangulation 
to handle the scattered data points. Then a 3D deformation registration was performed by 
Jonathan Plasencia using points picked by Morgan Giers from the affine registered pre-
contrast image and post contrast image. A transformation map was generated by Jonathan 
Plasencia by calculating the difference between current and desired point location for the 
points chosen, then interpolating all the surrounding pixel values using linear 
interpolation. The image volume was transformed using the same linear interpolation 
algorithm as in the affine registration. 
The T1 to concentration conversion equation (Eq 3.2) is only valid for a certain 
concentration range. Outside that concentration range there is nonlinearity in the actual 
concentration to T1 relationship that is not captured by the equation. The difference was 
quantified by scanning of a series of vials containing known concentrations of contrast in 
2wt% agarose, converting the average T1 value for each vial into a concentration. and 
comparing the calculated concentration to the actual concentration. 
 
3.2.5 Image Analysis 
Volumes of segmented contrast, including the cement implant, were calculated by 
Morgan Giers. These were adjusted by subtracting the volume of cement implanted, as 
calculated from the weight of the implant (see details of the surgical insertion). The 
volumes of the region where T1=na, which includes the cement implant and a region of 
extremely high concentrations of contrast (>50mM), was calculated. Total mass of 
contrast agent was calculated by summing all concentrations from pixels with a real T1 
value and multiplying by voxel volume (0.18 µL). 
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3.2.6 Statistics 
Volumes and total mass were analyzed by Morgan Giers for significance by two 
way ANOVA (wound types and presence of contrast agent: experimental IMR, 
experimental IOR, control IMR, and control IOR) using Minitab
®
 (Minitab Inc., State 
College, Pa, USA). All data used in ANOVA were confirmed to have a normal 
distribution through examination of the histogram of residuals and the normal probability 
plot. Post hoc t-Tests were performed when p<0.05 by ANOVA.  
 
3.3 Results and Discussion 
 
3.3.1 How Good are T1 Maps? 
Equation 3.1 was used to calculate T1 from the intensity values from a set of T1-
weighted images taken at different relaxation times (TR). The fitting is performed pixel-
by-pixel using equation 3.1. There is noise in the T1-weighted images; thus there is noise 
in the T1 value obtained. The noise in the T1 values depends on the signal to noise ratio 
(SNR) of the image acquisition method used. ln(S0/(S0-S)) is plotted vs. TR for a single 
pixel in the muscle of specimen 4 (Fig 3.2); the inverse of the slope is the T1 value, and 
an estimate of the error can be determined from the residuals (Fig 3.2). For the pixel in 
figure 2, the T1 value is 2500 ms, and the residuals squared are 0.96, indicating a good fit 
is achieved. Noise is visible as graininess in the T1 map image (Fig 3.1b). Including more 
values of TR decreases the error and improves the calculation, but requires longer image 
acquisition time. The time required for the scan is also a function of the TR values chosen, 
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number of slices, and resolution desired. For the 4 TR values used here (1463, 2000, 
3000, and 5000 ms), 42 slices and 0.3mm x 0.3mm resolution, a scan takes 14 minutes. 
Certain applications, such as imaging a beating heart, require a fast measurement time. In 
those cases, a 14 minute scan is unacceptable so a single T1-weighted image can be used 
in such cases 
81,83,86
. These methods typically result in greater error, but the error can be 
offset by acquiring a greater number of replicates.  
 
Figure3. 2: A plot of signal intensity from the T1 weighted images at different TR, for one 
pixel, used to determine T1 value.  
 
3.3.2 What does Filtering do? 
Next, the T1 map is filtered to decrease noise (Fig3.1c). Filtering increases confidence 
that voxels included as containing contrast are not a product of noise, but filtering also 
reduces the ability to detect small features in the image slice In order for a voxel to be 
included as having contrast, at least two neighboring pixels must also have contrast. 
Subsequently a single voxel that contains contrast  will be excluded from the image and 
that pixel will then be changed to the median value of the surrounding pixels.  Other 
sharp features such as tissue planes can be replaced or thinned with the surrounding 
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muscle tissue values, blurring the image. The higher the order of the filter, number of 
neighbors included, the more severe the effects of the filter. At the order used here, 5th 
order, much of the noise appears to be removed, but features such as tissue planes can 
still be seen.  
 
3.3.3 How Consistent is Segmentation? 
Next, the pixels containing contrast agent are identified (Fig 3.1e,f). Identification of 
contrast requires segmenting the contrast within certain tissue types. In order to see the 
main body of distribution the regions not connected to the main body are excluded. By 
only including regions that are connected within a single tissue type the regions of 
contrast are very reproducible. Even without restricting to a single tissue type in previous 
work by these authors, blinded reviewers chose areas of contrast from image slices 
thresholded at 1400 ms, and there was good agreement among reviewers (interclass 
correlation coefficient=0.92-0.96), indicating reproducible results 
99
. In the present work 
the method was made even more robust by thresholding at a level based on the 
longitudinal relaxation times within a single tissue, and including all connected voxels 
within that threshold.  
 
3.3.4 How Reliable are the Concentration Values? 
Concentrations were calculated by applying equation 3.  to each pixel containing 
contrast agent. Pixels with a T1 value of na were not assigned a concentration. The 
equation relates T1 with contrast concentration, but it is only accurate within a range of 
concentrations. At low concentrations, which produce T1 values close to native tissue, the 
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likely error between the calculated and actual concentrations is fairly large (Fig 3.3); 
however, the error is skewed so that the actual concentration is not likely to be much 
greater than the calculated value, but the actual concentration may be substantially less 
than the calculated value. At high concentrations, approaching the signal intensity 
saturation limit, an artifact occurs that yields T1 = na in the pixel of interest but can also 
effect the intensity of pixels nearby resulting in an incorrect image (Fig 3.4). The range of 
concentration between these high (saturation leading to artifact) and low (resulting in no 
contrast) values should be considered when choosing the amount of contrast agent to load 
into the drug delivery vehicle. The concentration of Gd-DTPA loaded into the ALBC in 
this study (67 mM) is great enough to allow for an artifact to occur. Most images are 
unaffected because the Gd-DTPA in the ALBC is not near water and, once it is released 
into the volume surrounding the ALBC, it quickly becomes diluted to less than the 
concentration causing artifacts; however, in some images, high concentrations near the 
femur cause spatial morphing indicating an artifact. The magnitude of the artifact was 
estimated by comparing the volume of pixels where T1=na between control and 
experimental implants. Regions where T1=na where regions where the T1 values were 
fitted by the software, but were calculated as too small to be reliable based on the shortest 
TR values which were several hundred milliseconds long. The region where T1=na 
includes the volume of the cement implant, which is not hydrated enough to be visible to 
on the MRI, and the volume of artifact surrounding the implant. There will be no artifact 
resulting for contrast agent in the control images. If there was a significant amount of 
artifact or super-threshold gadolinium near the implant in the images with contrast the 
volume of pixels where T1=na would be higher than in the control images. From the 
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ANOVA there is no statistically significant differences between the control and 
experimental (p=0.86), indicating that artifacts present are not large enough to 
significantly affect the experiment. The possibility of artifacts must be balanced against 
the necessity for visualization of contrast agent further away from the implant when 
choosing the Gd-DTPA loading amount.  
 
Figure 3.3: T1 maps were acquired for a series of different concentrations of Gd-DTPA 
prepared in agarose gel. The plot shows the difference between actual concentration 
(squares) and concentration calculated using equation 3.2 (dashed line) . 
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Figure 3.4: (a) T1-weighted image and (b) T1 map of a vial of 100 mM Gd-DTPA which 
creates an artifact. The dark portion of the images should be round, and the dark portion 
of the T1-weighted image should be bright. 
 
The histograms of five pre-contrast image volumes were analyzed to find the mean T1 
value of tissue containing no contrast agent (2817±852 ms) (Fig 3.5) to evaluate if a 
single value could be used across multiple animals. The mean (2817±852 ms) provided 
similar information to the histogram peak values (largest count number in the histogram) 
for the 5 rabbits shown (2815±132 ms). Animal to animal variability can be assessed by 
comparing a single histogram’s mean and standard deviation (2905±834 ms) to the mean 
from the compounded 5 rabbit histogram (2817±852 ms), whose deviation overlaps 
considerably. Despite the fact that T1,0 values can vary with metabolic activity, the animal 
to animal variability is small relative to the spread of the histogram.  Thus error from 
animal to animal variability is less than error due to differences within a single animal. 
This indicates that there is minimal error introduced by using the 2817 ms value for all 
animals rather than using a value determined for each animal. So while less error is 
introduced by using a different value evaluated for each animal, if it is not possible to 
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accurately evaluate a precontrast value a value from a different animal or an average 
value from multiple animals could be used. 
To quantify error likely resulting from using an isotropic value of T1,0 rather than a 
registered pre-contrast image volume to provide a pixel-by-pixel value of T1,0, Michael 
Caplan and Morgan Giers applied equation 3.2 to T1 values between 0 and  1965 using 
T1,0 = 2817 ms (mean), 3669 ms (+1 standard deviation), and 1965 ms (-1 standard 
deviation) (Fig 3.6). This provides a reasonable estimate of the effect that large 
variability in observed T1 would have on the calculation of concentration.  Equation 3.2 
applied to T1=1650 ms results in a concentration of 66 ±22/40 µM (where the first error 
number is the difference calculated using T1,0=3669 ms and the second number is the 
difference calculated using T1,0=1965 ms). As can be seen in figure 3.6, error becomes 
less as T1 decreases (actual concentration increases). Note that the error is unequal above 
and below the concentration. For T1=1965ms, using T1,0=3669 ms calculates a 
concentration value 54% greater than that calculated using T1,0=2817 ms; whereas, using 
T1,0=1965 ms calculates a concentration of 0 µM. (100% error). The error is always 
greater for lower concentrations. At low values of T1 (high concentrations), the error is 
minimal. For example, T1=51.5 ms results in a concentration of 5000 ± 20/40 µM 
(0.4%/0.8%). 
The uneven error results in concentrations that are more likely to be overestimated 
rather than underestimated. Hence, pixels included as having contrast are likely not 
overestimating the concentration, but may not actually contain contrast. The 
concentration calculation error will be greater in some areas than in others. For example, 
the femur has a broader histographic distribution than the total image, as shown in figure 
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3.7, so in the femur, error will be greater than the previous estimate. The muscle is more 
isotropic than the total image so the error for calculations performed in muscle will be 
slightly less than the previous estimate. Therefore, using an isotropic T1,0 value can give 
accurate order of magnitude information, but specific values, especially low 
concentration values, should be considered with caution. One potential clinical 
application of visualizing drug distribution is co-delivering Gd-DTPA with 
antimicrobials to determine if the infection is being treated effectively. For this 
application, the minimum effective concentration of antimicrobial is near the lower limit 
of detection of the isotropic T1,0 technique (20-200 µM). At that lower limit, if a pixel 
shows as containing contrast (T1≤2200ms), it may or not contain effective concentration 
of antimicrobial; however, if a pixel does not show as containing contrast (T1>2200ms), 
then it likely contains less than an effective concentration of antimicrobial. Therefore, it 
is unlikely that a patient would receive an additional intervention unnecessarily, but a 
patient requiring additional intervention could be evaluated to require no additional 
intervention allowing a risk that the infection could recur. 
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Figure 3.5: Histograms of 5 pre-contrast rabbit T1 maps: rabbit 1 (dashed grey line), 
rabbit 2 (solid grey line), rabbit 3 (dotted black line), rabbit 4 (dashed black line), rabbit 5 
(solid black line). 
 
Figure 3.6: Estimation of percent difference from concentrations calculated with an 
isotropic T1,0=2817 ms (mean, solid line), 3669 ms (upper limit, dashed line), and 1965 
ms (lower limit, dotted line). 
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Figure 3.7: Histograms of the total image (solid grey line), the muscle tissue (solid black 
line), and the bone (dashed black line) in a pre-contrast T1 map.  
  
3.3.5 How does the Isotropic T1,0 Method Compare to Other Methods? 
Next this group compare and contrast results when a single isotropic value of T1,0 
is used (as described above) versus when T1,0 values are taken from image volumes of the 
tissue prior to addition of contrast agent. Images of a pre-contrast and post contrast 
FTMB procedure are shown in figure 3.8. Figure 3.8a (left) shows a pre-contrast image 
that has not been altered, figure 3.8b (left) shows the same image but registered to the 
post-contrast image using an affine registration (rigid body registration); figure 3.8c (left) 
shows the same image but registered to the post-contrast image using a deformation 
registration; and, finally, figure 3.8d (left) shows the isotropic T1,0 method in which a 
single value of T1,0 is applied to all of the pixels in the region of interest. It is apparent in 
figure 3.8a-c (right) that the edges of the legs do not perfectly overlap (large red region in 
concentration map) in the unregistered, affine registered, or deformation registered 
images; but the isotropic T1,0 concentration map (Fig 3.8d, right) does not have 
significant patches of red surrounding the leg indicating that this is not a problem for the 
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isotropic T1,0 method. The rigid body transformation (Fig 3.8b) was performed by 
choosing points on the femur, which is a rigid anatomical feature. While the 
transformation worked well for the femur, the surrounding soft tissue is not registered 
using an affine technique. The registration with deformation was applied to register the 
soft tissue (Fig 3.8c); however, several factors made the registration with deformation 
method less capable of describing the transform well. It was difficult to identify 
landmarks to register by in the muscle tissue and especially the fat marrow tissue. 
Furthermore, choosing the number of corresponding points necessary to obtain a better 
transform in 3D would be impractically time consuming (250 points takes ~4 hours). 
Even though the registration with deformation was not perfect, it seems to perform better 
than the isotropic T1,0 method for some anatomic features having T1,0 values different 
from the tissue mean. For example, in Figure 8d (right), fairly thick features appearing to 
have non-zero contrast agent concentration appear. These features also appear in the 
registered concentration maps (Fig 8b, right, and 8c, right), but the features are generally 
fewer and thinner. This indicates that, for anatomical locations such as the brain, which is 
less isotropic than the muscle, registration may be more necessary and practical. The 
brain is simpler to register because of lack of deformation and multiple landmarks to 
register by. There are many groups working on performing and automating registration 
techniques that could be useful if registration were required 
65,109-113
. Regardless of the 
strengths and weaknesses of each method, within the region likely containing contrast 
agent (bottom left corner of the leg), all four methods seem to perform well, and no major 
differences are noted among the methods. There are slight differences in the 
concentrations calculated in the isotropic T1,0 method near the edge of the leg; however, 
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these differences are not likely to affect conclusions drawn from these data since animal-
to-animal variability is likely greater than error due to the value of T1,0 used. It should be 
noted that even though the registration and isotropic T1,0 methods give similar results for 
this application, the isotropic T1,0 method is far less time consuming and has the practical 
benefit of not requiring a pre-contrast image (which requires that the animal be scanned, 
removed from the scanner, and then implanted with the local drug delivery vehicle). For 
applications where the pre-contrast and post contrast image could be obtained without 
removing the subject from the MRI, such as when the contrast or delivery vehicle is 
injected, the pre-contrast image could easily be used for T1,0 without needing to perform a 
registration. Therefore, the practicality of a method for a specific anatomical region and 
the expected performance of a method for that anatomical region should be considered 
when choosing whether to use a registration technique or an isotropic T1,0 method. 
 
Figure 3.8: (a) The unregistered images, (b) affine registered images (performed by 
Jonathan Plasencia), (c) registration with deformation (performed by Jonathan Plasencia), 
(d) constant T1,0, where the left image is T1,0, middle left image is T1, and middle right 
image is the concentration map resulting from those T1,0 and T1 images, where white is 
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where the calculated region of cement is, and the right image is the difference between a-
c and d. 
 
 
Figure 3.9: A comparison of concentration maps and 3D Mimics reconstructions of an 
IMR and IOR without (left) and with (right) contrast agent mixed into the ALBC. 
 
3.3.6 What Practical Information can this Method Provide? 
Figure 3.9 show concentration maps and 3D reconstructions for an IMR and IOR of 
the control and experimental cement composition.  Visual examination of the sagittal 
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concentration maps from the data set show contrast above and below the IMR. The 
isotropic T1,0 contrast concentration calculation method calculates a significant difference 
in volume of distribution between control and experimental animals with an IMR 
(p<0.0001) (Fig 3.9); however, calculated no significant difference between control and 
experimental IOR (p≈0.5). When the same implants were compared with total mass of 
contrast agent observed as the metric, again the IMR showed significance (p≈0.004) and 
the IOR showed no significance (p≈0.8). One limiting factor for calculating contrast 
concentration within the intramedullary space is the multiple tissue types present in the 
surrounding area. In this work concentration calculations were restricted to only the 
intramedullary space, but contrast could easily be present in the bone surrounding the 
intramedullary space as well as proximally and distally. By excluding these other regions 
the contrast calculations are restricted to a uniform volume, making the difference in 
volume of distribution very difficult to calculate. The results could possibly be improved 
if all the tissue types in that leg (muscle, several types of bone, and intramedullary space) 
were accounted for but this is difficult and time consuming to accomplish.   
 
2.4 Conclusions 
This chapter demonstrates a simple to use method for imaging local drug delivery 
and calculating its local concentration with good spatial and temporal resolution. This 
method has broad applications in the field of drug delivery, but here is shown applied to 
delivery from ALBC for the treatment and prevention of infection in orthopaedic 
applications. This group identify and quantify sources of error in this method and suggest 
ways to minimize these errors. Specifically,  this group discuss how to generate images 
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with T1 values in the range that will yield accurate concentrations and avoid artifacts 
from excessive concentration of contrast agent, the strengths and weaknesses of several 
methods of generating T1,0 values for use in converting from T1 to concentration, and 
methods for using these data to statistically compare contrast agent distributions between 
wound models. 
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Chapter 4. DISTRIBUTION PATTERNS OF LOCAL DRUG DELIVERY IN 
ORTHOPAEDIC WOUNDS USING MRI 
 
4.1 Introduction 
Orthopaedic infection is a serious problem affecting many patients' physical and 
financial wellbeing. Infections of orthopaedic implants, and surrounding bone and joints, 
can result in increased pain, loss of function and productivity. Approximately 1-2 % of 
primary arthroplasties result in a surgical site infection 
11,12
. In trauma cases the rate of 
infection is 9.4% 
13
. There is an estimated 112,000 total orthopaedic infections per year 
16
, a figure expected to increase as the projected number of arthroplasties increase by 
several fold over the next 18 years 
18
. Each infection results in a $15,000-250,000 
increase in healthcare cost 
16,17
. It was estimated a total of $1.8 billion was spent on 
increased medical costs due to orthopaedic infection of total joint arthroplasties in the US 
in 2004 
16
, and is likely more every year. 
Orthopedic infection is a complex problem because they are the result of biofilm 
forming microbes, such as Staphylococcus aureus. Not only do biofilms cause a barrier to 
antimicrobial transport, microbes in established biofilms are less susceptible to 
antimicrobials 
22
. Therefore, antimicrobial concentrations 100-1000x minimum inhibitory 
concentration (MIC) are required to kill organisms in biofilm 
25,26
. Since antimicrobial 
action is time and concentration dependent, these high concentrations need to persist to 
be effective. For instance, biofilm methacillin-resistant Staphylococcus aureus takes 
more than 5 days of exposure to 2 mg/mL Vancomycin to be eradicated 
29
.  
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Clinically, orthopedic infections are often caused by implanted devices, but can 
involve the surrounding bone and joints. Therefore, removal of the implant followed by a 
2 stage plan resection of dead and dysvascular tissue is necessary. Dead space is managed 
by filling the volume with antimicrobial loaded bone cement (ABLC). The ABLC is 
intended to treat any biofilm fragments left during debridement as well as any planktonic 
bacteria in the surrounding muscle substance. Since microbes thrive on implant surfaces 
the treatment of infection requires a period of delay during local antimicrobial delivery, 
before reconstruction and re-implantation can occur. Treatment often fails because of 
longer operations or incomplete debridement performed by less practiced surgeons. To be 
effective, locally delivered antimicrobials should cover the entire volume of the surgical 
wound, where biofilm debris might be present after the surgery, as well as penetrate into 
the surrounding muscle to manage any incomplete resection.  
There is a long history of in vitro research focused on elution kinetics of 
antimicrobial loaded bone cement of varying compositions 
9,46-49
. These experiments are 
usually performed in near infinite sink condition, where standardized specimens are kept 
in relatively large volumes of well mixed aqueous fluid at 37
 °
C 
46,47
. Since elution of 
drugs from biomaterials is surface area and volume dependent, having known shapes and 
external conditions allows researchers to calculate transport properties of the material. 
Elution studies give valuable information for comparing different vehicles in similar 
environments, but is less useful for predicting in vivo behavior. In vivo there are complex 
environments that effect not only where antimicrobials distribute to, but how they are 
delivered. For instance, bone is a barrier to antimicrobial transport. The effective 
diffusion coefficient in bone (Deff=7.8x10
-7
 cm
2
/s) 
51
 is much lower than in muscle 
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(D=1.38x10
-5
 cm
2
/s) 
52
. When antimicrobial loaded cement is in bone there will be an 
accumulation of antimicrobial between the bone and the cement. The accumulation will 
decrease the driving factor for antimicrobial delivery from the cement and delivery from 
the cement will decrease. Therefore, in vitro testing cannot predict in vivo concentration 
over time and location. 
To gather information on the in vivo behavior there have been some research 
collecting fluid samples and biopsies 
1,2,53
. While these methods give more information 
about how antimicrobials deliver from cement in vivo, they can only capture the 
concentration of antimicrobial in the sample location at the timepoint the sample was 
taken. Cierney et al. studied in vivo patient outcomes to determine treatment efficacy, but 
clinical outcomes do not provide information on the mechanism behind treatment success 
58
.  
Medical imaging has been used to visualize drug distribution in vivo in real time. 
Magnetic resonance imaging (MRI) has been used to study the distribution of contrast 
agents locally delivered from catheters to glioblastomas 
75,76
. The distribution of contrast 
agent from an ocular implant has been reported 
87
. Previous work by McLaren, Caplan, 
and co-workers found locally delivered Gd-DTPA could be seen on MRI and was 
affected by delivery vehicle type and location 
99
. In that experiment a common, clinically 
used, MRI contrast agent gadolinium diethylenetriaminepentaacetate (Gd-DTPA) was 
used as a surrogate for antimicrobials.  
Gd-DTPA is a fairly accurate model for antimicrobials because it has a similar 
solubility and diffusion coefficient (D=4.0 x 10
-6
 cm
2
/s) 
89
 to the antibiotics Gentamicin 
(D= 2.1 x 10
-6
 cm
2
/s)
23
 and Vancomycin (D= 3.6 x 10
-6
 cm
2
/s) 
90
. Gd-DTPA affects the 
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motion of water molecules, causing their longitudinal relaxation to decrease. Like all 
MRI contrast agents Gd-DTPA is only visible in areas that are hydrated. Areas of low 
hydration, such as inside bone and bone cement will not show Gd-DTPA.  
In this chapter Gd-DTPA distribution is imaged distributing from bone cement 
into orthopaedic wound models. The research questions for this study are: is distribution 
of contrast agent following local delivery detectable on MRI? Can contrast concentration 
be quantified on MRI? Does surgical wound environment affect distribution of contrast 
following local delivery? 
This research was conducted as a collaboration between Morgan Giers, Alex 
McLaren, Kenneth Schmidt, Michael Caplan, and Ryan McLemore.. Specific 
contributions of each team member are stated in the corresponding sections in the 
methods; however it should be additionally noted that Morgan Giers, Alex McLaren, 
Michael Caplan, and Ryan McLemore participated in analyzing and interpreting the data.  
 
4.2 Methods: 
 
4.2.1 Delivery Vehicle Fabrication 
Local delivery depots were created by Morgan Giers, Ryan McLemore, and Alex 
McLaren using Simplex P® (Stryker, Kalamazoo, MI, USA) PMMA bone cement. The 
control vehicles were made using the manufacturer's instructions (67wt% PMMA and 
33wt% MMA) and included no contrast agent or porogen. The experimental implants 
were made using 57wt% PMMA, 29wt% MMA, 3wt% Gd-DTPA, and 11wt% 250-425 
µm diameter xylitol as a porogen. 1 cm x 3 mm diameter rods were fabricated prior to 
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implantation using a red rubber catheter as a mold (Covidien, Mansfield, MA,USA). The 
delivery vehicles that were used to fill wound dead space were fabricated intra-
operatively. 
 
4.2.2 Surgical Procedure 
Two different wound models were created by Alex McLaren and Kenneth 
Schmidt using female New Zealand White rabbits. For the full thickness muscle and bone 
removal wound (FTMB), a full thickness of muscle and part of the cortex of the femur 
was removed. Specifically, a 4 cm incision was made in the ventral thigh of the animal. A 
1 cm x 1cm portion of muscle was removed all the way to the bone, 1.1±0.3 g of tissue, 
with a lexelle ronjeur. Then, a 1cm x 4 mm window was made in the cortex of the femur 
using a drill with a 6 mm acorn burr. Two cement rods, 4 mm in diameter and 4.5 cm 
long, molded with a slight curve to mimic the curvature of the femur, were inserted in 
either direction from the window into the intramedullary canal. An additional 1.5 ml of 
cement was used to fill the inside of the femur exposed from the window as well as the 
void space of the removed muscle. The portion of cement used to fill the void space of 
the removed muscle was formed into a rectangular shape. The muscle and fascia lata 
were left open and only the skin was closed. 10 rabbit legs total were given FTMB 
wounds, with 6 legs receiving experimental delivery vehicles and 4 receiving control 
vehicles. For the partial muscle removal wound (PTM), a partial thickness of muscle was 
removed and the femur was left intact. In the second model only the deep half the 
thickness of the muscle was removed and there was no bone removal. The mass of the 
muscle removed was 0.6±0.1 g. In the PTM model 1 ml of cement was used to fill the 
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removed muscle space. The muscle was closed over the implant, as well as the superficial 
layers. 8 rabbit legs total were given PTM wounds, with 6 legs receiving experimental 
delivery vehicles and 2 receiving control vehicles. 
 
4.2.3 Image Acquisition 
All images were taken by Qingwei Lui with a Bruker Biospin® 7-T MRI (Bruker 
Biospin, Billerica, MA, USA). T1 weighted, rapid acquisition with relaxation 
enhancement (RARE), images were collected of the upper legs, knee to hip, of the 
rabbits. Each of these T1 weighted images consisted of 42 fat-suppressed coronal slices, 
2mm thick, with voxel sizes of 0.3 mm x 0.3 mm x 2 mm. A series of these T1 weighted 
MRI images at different repetition times (TRs) (1463, 2000, 3000, and 5000 ms) were 
obtained 5.5 hours after implantation of the cement. T1 maps were obtained from the T1 
weighted image series by fitting them to the Bloch equation 
63
, using Bruker software.  
 
4.2.4 Euthanasia 
At the conclusion of imaging, animals were euthanized with 120 mg/kg 
Beuthanasia D solution. All procedures were compliant with the National institute of 
Health guidelines for the care and use of laboratory animals and approved by the 
Institutional Animal Care and Use Committee (IACUC). 
 
4.2.5 Image Processing 
All image processing was performed by Morgan Giers with significant input from 
David Frakes, Ryan McLemore, and Michael Caplan. Filtering and masking of MRI 
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images was done using MATLAB (The Mathworks, Inc., Natick, MA, USA). The T1 
maps were filtered with a 5th order median filter to reduce the noise. The filter changes a 
pixel to the median value of a group of pixels including itself and the 4 pixels 
surrounding it. The T1 maps were also masked with a binary mask of the T1 weighted 
image, which was less noisy than the T1 map, to remove all noise from outside the leg 
area.  
The segmentation of the region of contrast was completed using Mimics 
(Materialise, Leuven, Belgium). The cleaned T1 map was thresholded at a T1 value of 
2200 ms. The area of contrast, as determined by an observer, was then selected from the 
thresholded image. Small areas of contrast, less than 100 pixels, not connected to the 
main body of the contrast were excluded. The segmented area containing drug was used 
to construct a 3 dimensional representation of the drug distribution. The femur and legs 
were segmented in Mimics using the T1 weighted image to provide anatomical 
references. The rectus femoris muscle was segmented in Mimics using a built in user 
guided gradient edge detection algorithm. The mask was smoothed using a 0.8 smoothing 
factor with 2 iterations. The smoothed mask was corrected manually.  
The segmented areas were then imported back into MATLAB to construct 
concentration maps. The area of contrast was transformed into approximate contrast 
concentrations using the equation 
 
  
 
 
    
     
80,114
, where T1 was the T1 map value, 
T1,0 was the pre-contrast T1 value, r1 was the relaxivity constant, and C was the 
concentration. The T1,0 value used was the mean histogram value from 5 pre-contrast 
images. The area where the T1 value was na was made red, the greatest value in the 
concentration map. The area where T1=na included bone cement and the region where the 
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signal was saturated by high concentrations of drug. The concentration map and saturated 
region were superimposed on the T1 weighted image.  
 
4.2.6 Statistics 
Volume of distribution was calculated for the extrafemoral space by Morgan 
Giers, included all contrast agent and cement implant outside the femur. Only the 
extrafemoral space was calculated because the volume of cement was equal between 
wound types outside of the femur. General linear form ANOVAs were performed in 
Minitab (Minitab Inc., State College, PA) for all volumes vs. wound model type and side 
to compare control to experimental implants. General linear form ANOVAs were 
performed by Ryan McLemore and Morgan Giers for experimental implant volumes vs. 
model type and side to compare the two experimental implants. All data used in ANOVA 
were confirmed to have a normal distribution through examination of the histogram of residuals 
and the normal probability plot. Post-HOC t-tests were used for any significant findings 
from the ANOVA. The accuracy of the ANOVA's were verified using the R
2
 values. 
 
4.3 Results 
 
4.3.1 Can It be Seen? 
The unmodified T1 weighted MRI images are high resolution images with little 
noise (Fig 4.1a). Small anatomical features including the skin are clearly visible. Bone 
cement appears dark, and is visible as a region extending from the femur to the skin of 
the top leg (Fig 4.1a). Contrast is visible as bright pixels surrounding the cement region. 
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The unmodified T1 maps, which give the T1 relaxation times as calculated from several 
T1 weighted images, are high resolution images with a large amount of noise (Fig 4.1b). 
Both contrast and bone cement are visible as a dark region. The filtered and masked T1 
maps have less noise in the legs and practically no noise outside the legs (Fig 4.1c). The 
level of 2200 ms was chosen for the thresholded image because it included all visible 
contrast as determined by a group of experts. To remove artifacts the contrast was 
segmented from the thresholded image (Fig 4.1d). To accomplish the segmentation all 
contrast in the muscle and femur was segmented. Then, all pixels connected to the 
implant within that region were segmented. The concentration calculation produces a 
map where the majority of concentration values are in the 14-100 µg/mL range (Fig 
4.1e). When the segmented region includes a T1 value of na is plotted red (Fig 4.1f). The 
red region includes both cement and artifact where contrast concentrations are too high to 
distinguish from cement. The 3d reconstruction shows a rough edged volume containing 
contrast and cement (F4.ig 1g). The 3d reconstruction shows distinctive patterns, such as 
contrast distributing under the skin.  
There is a statistically significant difference in volume of distribution between 
images with contrast (2674+1140 mm
3
) and images without contrast (956+813 mm
3
) 
(p<0.001), indicating contrast is agent is readily visible.  
 
4.3.2 Can Concentration be Measured? 
Concentration maps show profiles consistent with known transport phenomena. It 
is expected that concentrations should be highest near the implant and lower farther from 
the implant (Fig 4.2). This concentration profile is seen consistently in all non control 
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images. Two discrete regions are analyzed at 5.5 hours (Fig 4.3). Region 1 (furthest from 
the femur) has a measured concentration of 34±39 µg/mL. Region 2 has a measured 
concentration of 133±63 µg/mL. These two concentrations are statistically different 
(p<0.001, t-test).  
 
4.3.3 Does Surgical Wound Environment Affect the Distribution of Locally Delivered 
Gd-DTPA (Antimicrobial Surrogate) ? 
Some commonalities are apparent in distribution pattern between the two surgical 
wound types. In both surgical models some penetration into muscle tissue is visible, but 
there is considerable preference to movement along intramuscular septa and connective 
tissue. There was an also observed difference in the distribution pattern of agent between 
the two types of wounds (Fig4.4-4.5). When muscle and fascia were left open in the 
FTMB wound, drug is observed throughout the damaged muscle layer, and can be 
observed to distribute under the skin (Fig 4.2 d-f, Fig 4.5). The volumes of the 
distributions between the PTM (1940 mm
3 
+ 771 mm
3
) and FTMB (2422 mm
3
+ 981 
mm
3
) wounds however where not statistically different (p=0.3) 
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Figure 4.10: Schematic of how concentration maps are made. (a) T1 weighted image (b) 
T1 map (c) filtered and masked T1 map (d) segmentation (e) concentration map (f) region 
where the T1 value equals 0 (g) superimposed concentration map and T1 equal to zero 
region on a T1 weighted image (h) 3D reconstruction of the segmented region. 
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Figure 4.2: (a) and (b) are coronal concentration maps from PTM wounds at 5.5 hours, 
(c) is a Mimics
® 
3D reconstruction of (b). (a) is a control depot and (b) is a Gd-DTPA 
depot . (d) and (e) are coronal concentration maps from FTMB wounds at 5.5 hours, (f) is 
a Mimics® 3D reconstruction of (e). d) is a control depot and (e) is a Gd-DTPA depot . 
The color gradient bar at the top represents the Gd-DTPA concentration. Dark blue is low 
concentration, red is high concentration or signal saturation.   
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Figure 4.3: Region selection from a single slice FTMB model at 5.5 hours. Selected slice 
is diaphyseal, near the middle of the femur. Selected regions are indicated with white 
outlines. Region 1 has a measured concentration of 34±39 µg/mL. Region 2 has a 
measured concentration of 133±63 µg/mL.  
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Figure 4.4: 3 angles of a Mimics® 3D reconstruction of a partial thickness muscle 
removal surgical model with contrast (experimental rabbits 1-3) and without contrast 
(control rabbit 1). 
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Figure 4.5: 3 angles of a Mimics® 3D reconstruction of a full thickness muscle and bone 
removal surgical model with contrast (experimental rabbits 1-3) and without contrast 
(control rabbit 1). 
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4.4 Discussion 
Compared to previous methods
1,115
 MRI visualization gives more detail and is 
less invasive to human patients. Since the images show an anisotropic distribution, using 
a biopsy or fluid collection method gives results dependent on the location the sample 
was collected from. For instance, in studies where wound fluid is collected 
1
, the 
concentrations might be higher than the concentrations achieved in nearby muscle. 
Visualizing drug distribution using MRI could be used in human patients, individually, in 
real time to observe if the treatment is likely to be effective. 
There are several limitations of this study. The first limitation of this study was 
the short, 5.5 hour, period of time data was collected, compared to the ~28 days of 
expected delivery 
2
. This experiment was meant to visualize the differences between 
wounds and not the time course of delivery. Second, rabbit anatomy is different from 
human anatomy. Rabbits have very loose connective tissue between muscle groups and 
they have a tendency to pull apart, creating a space between the muscles. Rabbits also 
lack the subcutaneous fat that most humans have. The difference in anatomy might result 
in exaggerated anisotropy of distribution of contrast in the rabbit model because of the 
extra space between muscles. Third, Gd-DTPA is not an active antimicrobial agent. Their 
transport properties based on solubility and diffusion coefficients are theoretically very 
similar in the tissue, but the antimicrobial could bind or get intracellularized while Gd-
DTPA does not. Further work is needed to determine if any factors would cause Gd-
DTPA and antimicrobials to distribute differently. Finally, the cut tissue from the surgery 
cause the presence of methemaglobin, which shows up bright in the T1 weighted image 
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and is indistinguishable from the contrast agent 
116
. The methemaglobin problem is 
mostly resolved in the T1 map, where the methemaglobin is much less sensitive than the 
contrast agent. 
Even with the limitation of this work there are clear differences between the 
distributions in images with contrast and images without contrast. The visible and 
statistical differences show that MRI is a reliable method for detecting distribution of 
contrast agents from local delivery depots. 
While locally delivered Gd-DTPA concentrations can be quantified on MRI, there 
are several assumptions necessary to make this calculation. These assumptions can 
introduce error into the calculation. This group has estimated these errors and discussed 
them at length in a chapter 3 
105
. Briefly, T1,0 was used in place of a perfectly registered 
pre-contrast image, so that a pre-contrast image is not necessary, hence making MRI 
visualization of drug distribution more clinically viable. The T1,0 used here was a mean 
value from the histograms of 5 pre-contrast rabbits. The standard deviation of those 
histograms was used to determine a theoretical error in the concentrations calculated. The 
standard deviation was used instead of a confidence interval because the standard 
deviation was larger and hence a more conservative number. Using this technique the 
sensitivity limit was calculated as 14 µg/mL and produced concentration estimates of 0 to 
26 µg/mL. The error decreases as the concentration increases. Overall, it was shown that 
the error was not so large that practical differences in animal experiments could not be 
seen. Clinically, therapeutic ranges for treatment of biofilm associated infections is 100-
1000's of µg/mL 
25
. Therefore, if antimicrobial surrogate is visible on the MRI it is likely 
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at a therapeutic level. If antimicrobial surrogate is present at a sub-visible concentration it 
is likely not at a therapeutic level and is irrelevant to the purpose of this experiment. 
There are differences seen qualitatively in the distribution locations between the 
two types of wounds. Small closures in tissues such as fascia lata are a significant barrier 
to transport. These distributions, however, do not have statistically significant different 
volumes. Both wounds also have the commonality that contrast remains within a few 
centimeters of the wound site and does not cover the entire leg. Most of the contrast agent 
is seen in the wound site and intermuscular tissue planes. It is unknown if these 
differences will scale to human subjects or larger animals, based on the differences 
between human and rabbit anatomy. It is seen that there is a large variability between 
animals with the same wound type. The variability indicates that distributions clinically 
could vary widely between patients. MRI could potentially be used as a tool to assess the 
concentrations achieved in an individual patient after surgical intervention. 
 
4.5 Conclusions 
In conclusion, the use of MRI gives more information than previous methods to 
determine in vivo distributions of contrast from local delivery vehicles. This method is 
applicable to human patients and could potentially be used clinically to confirm it 
treatment was likely to work.  
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Chapter 5. DEVELOPMENT AND CHARACTERIZATION OF MRI VISIBLE 
ANTIMICROBIALS 
 
5.1 Introduction 
In chapters 2-4 a method was outlined for how MRI imaging of contrast agent 
distribution from bone cement can be used to acquire the spatiotemporal distribution of 
drugs in vivo. That work is performed to assess how antimicrobials might distribute in 
surgical wounds to treat orthopaedic infection. In order to further study this problem it is 
desirable to use a molecule that has therapeutic ability, but can be seen on MRI. Such a 
molecule would potentially serve as a better model for studying antimicrobial 
distributions in orthopaedic infections because if it maintained biological activity it 
would have the same binding properties of an antimicrobial, where Gd-DTPA alone does 
not. In this work conjugation of two different antimicrobials, gentamicin and 
vancomycin, to MRI contrast agents will be attempted.  Both of these antibiotics are 
commonly used in orthopaedic surgery.  Gentamicin is primarily used for gram-negative 
bacteria, but shows bactericidal effects for some gram-positive bacteria as well (Fig 
5.1b).  It acts by binding and repressing ribosomal activity.  Vancomycin is only active 
against gram-positive bacteria (Fig 5.1c).  It acts by binding the peptidoglycan layer of 
the cell wall and preventing transglycosylating crosslinking. 
The antibiotics will be bound to 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid  (DOTA), a chelator, and then use the DOTA to chelate Gd
3+
 ions. In 
order to bind these antibiotics to DOTA an aqueous 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) reaction will be used 
117-121
.  In an EDC 
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mediated reaction a molecule with a carboxylic acid, in this case DOTA has 4 carboxylic 
acids, binds with EDC to form an unstable O-acylisourea intermediate. When N-
Hydroxysulfosuccinimide (Sulfo-NHS) is introduced it replaces the EDC and forms a 
semi-stable NHS-ester bond with DOTA.  The Sulfo-NHS is then replaced by a molecule 
with a primary amine; gentamicin has 3 primary amines and vancomycin has 2.  The 
replacement of Sulfo-NHS by an antibiotic forms an amide bond between the DOTA and 
antibiotic. The DOTA can be used to chelate free gadolinium ions, making the molecule 
potentially MR visible. M Lewis et al. successfully used EDC/Sulfo-NHS chemistry to 
conjugate proteins with primary amines and DOTA 
118,119
. Prodhomme et al. successfully 
conjugated a poly glutamic acid polymer to vancomycin using an EDC mediated reaction 
and found it maintained bactericidal activity 
122
. J Lewis et al. conjugated antibodies to 
gentamicin using an EDC reaction and found that gentamicin also maintained its 
biological activity when bound 
123
. 
This research was conducted as a collaboration between Morgan Giers, Alex 
McLaren, Ryan McLemore, and Michael Caplan.  
 
5.2 Methods: 
 
5.2.1 Conjugate Preparation 
Conjugation protocol is developed by Morgan Giers and Ryan McLemore with 
input from Veronica Clavijo Jordan and Derek Overstreet. Conjugates were prepared by 
Morgan Giers, Ethan Province, Adam Roussas, and Mathew McDermand. Conjugates are 
prepared using a two step Sulfo-NHS and EDC mediated primary amine to carboxylic 
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acid reaction. In the first step molar ratios of 1:4:4 of  DOTA:EDC:Sulfo-NHS 
respectively are added to a 0.1 mM MES buffer at 4ºC and the pH is adjusted to 5.5. The 
reaction is allowed to stir for 30 minutes. After that initial 30 minutes gentamicin or 
vancomycin is added to the reaction in a 1:1 molar ratio with DOTA and the pH is 
adjusted to 7.4. The reaction was allowed to stir for 24 hours.  
After the antimicrobial to DOTA conjugate is prepared it is used to chelate 
gadolinium. Chelation is done by adding 0.95:1 molar GdCl3 to DOTA and adjusting the 
pH to 6.5 using 0.1N HCl. The reaction is heated to 85-95ºC and stirred for 30 minutes. 
In both steps phosphate buffers are avoided because it can deactivate EDC 
124
 and bind 
with gadolinium ions forming insoluble precipitates 
125
. 
 
5.2.2 High Pressure Liquid Chromatography 
Analytical high pressure liquid chromatography (HPLC) is performed to  separate 
the molecules and determine yield. The following procedures were developed and 
performed by Morgan Giers and Ethan Province. The mobile phase for the gentamicin 
conjugate is 30% methanol and 70% water. The column used is a 4mmx25 cm 5um 
normal phase column. The conjugate is run isocratically for 30 minutes.  Elution was 
monitored with absorbance at 254 nm. The mobile phase for the vancomycin conjugate 
starts at 10% acetonitrile and 90% water, then, steadily over 15 minutes raises to 70% 
acetonitrile and 30% water. The column used is a 4mmx25 cm 5um Agilent C18 column.  
Elution is monitored with absorbance at 254 nm. 
 
5.2.5 Mass Spectrometry 
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Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass 
spectrometry is performed by Morgan Giers, Adam Roussas, and Mathew McDermand to 
determine molecular weights of the product. All mass spectrometry for the gentamicin 
conjugate is performed in a 4-Hydroxybenzylidenemalonitrile (4-OH) matrix.  All mass 
spectrometry for the vancomycin conjugate is performed in a 2,5-Dihydroxybenzoic acid 
(DHB) matrix. 
 
5.2.5 Xylenol Orange Assay 
A xylenol orange assay is performed by Morgan Giers and Adam Roussas with 
input from Ryan McLemore to determine the amount of unchelated Gd
3+
 ions left after 
the chelation step. Xylenol orange is a colorimetric assay where the dye appears purple 
when bound with Gd
3+
 and yellow when unbound 
126
. More specifically xylenol orange is 
a weak chelator with four carboxilic acid groups. When the molecule loses H molecules, 
such as in the chelation of a metal ion or alternatively when in a high pH solution, it turns 
from yellow to purple. The xylenol orange assay is performed by creating a standardized 
curve using molar ratios of xylenol orange to GdCl3 of 1, 0.5,0.1,0.05, and 0.01. The post 
chelation reaction with 0.00014 mmols of gadolinium is added to a 0.0001 mM solution 
of xylenol orange to get good sensitivity to unbound gadolinium. The absorbance for all 
samples are measured for wavelength of light between 400 and 700 nm. Then the 574 nm 
absorbance is divided by the 434 nm absorbance for each sample to obtain the yellow to 
purple ratio. All of these values were plotted vs. molar ratios of xylenol orange and 
GdCl3. The amount of unbound GdCl3 in the reaction sample was calculated by 
comparing it to the trend line from the standardized curve.  
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5.3 Results 
 
5.3.1 Was the Conjugation of Antimicrobial to DOTA Successful? 
Mass spectrometry of DOTA-gentamicin conjugate reveals a peak at 850.8 Da, 
which is the predicted molecular weight of the desired product plus a hydrogen adduct 
(Fig 1a). The 850.8 Da peak is not present in the gentamicin sample alone (Fig 5.1b) and 
therefore indicates a conjugation of gentamicin to DOTA. Mass spectrometry of the 
DOTA-vancomycin conjugate gives a peak at 1836.7 Da, the predicted molecular weight 
of the desired product plus a hydrogen adduct (Fig 5.2a). This peak is also absent in the 
vancomycin only sample (Fig 5.2b). In both the DOTA-gentamicin and DOTA-
vancomycin conjugates the peak height in comparison to the gentamicin and vancomycin 
peaks in their respective samples indicates a relatively low but significant amount of 
conjugate is present, although mass spectrometry is not a quantitative method to 
determine precise yield. 
In addition to mass spectrometry, HPLC is performed on each sample to 
determine if the conjugate can be separated from the rest of the reaction mixture. HPLC 
of the gentamicin conjugate does not show peaks for either the gentamicin or conjugate 
because the absorbance of those molecules is low (Fig 5.3). The absence of gentamicin or 
conjugate peaks on the HPLC indicates that it is unknown if the conjugate can be purified 
using HPLC. HPLC of the vancomycin conjugate however does give a new peak for the 
conjugate that is resolved from the other peaks, at ~18 minutes (Fig 5.4). The resolved 
peak indicates that DOTA- vancomycin can be purified using HPLC.  
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Figure 5.1: Mass spectrometry of (a) DOTA-gentamicin and (b) gentamicin only. 
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Figure 5.2: Mass spectrometry of (a) DOTA-vancomycin and (b) vancomycin only. 
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Figure 5.3: HPLC of DOTA-gentamicin (red) as well as all molecules used in the 
reaction including DOTA (green), sulfo-NHS (grey), EDC (yellow), and gentamicin 
(black). 
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Figure 5.4: HPLC of DOTA-vancomycin (red) as well as all molecules used in the 
reaction including DOTA (green), sulfo-NHS (grey), EDC (yellow), and vancomycin 
(black). 
 
5.3.2 Was the Chelation of Gadolinium Successful? 
To determine if the chelation of gadolinium is successful, a xylenol orange assay 
is performed. When the chelated sample is compared to the standardized curve, it 
indicates that there is 6% unbound gadolinium in the Gd-DOTA-gentamicin sample and 
1% unbound gadolinium in the  Gd-DOTA-vancomycin sample (Fig 5.5). Therefore, 
most of the gadolinium was successfully chelated.  
 
Figure 5.5: Graph of xylenol orange assay where the diamonds are a standardized curve 
of known concentrations, the triangle is for Gd-DOTA-gentamicin conjugate, and the 
square is for the Gd-DOTA-vancomycin conjugate. 
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5.4 Discussion 
The results show that two different antimicrobials with primary amines, gentamicin and 
vancomycin, can be conjugated to DOTA and subsequently used to chelate gadolinium. It 
is expected that both vancomycin and gentamicin will retain their antimicrobial activity 
as in other studies where molecules where attached to the same location they maintained 
antimicrobial activity 
122,123,127
. It is also expected that both of these conjugates will be 
MR visible. Gd-DOTA is a currently used MRI contrast agent. MRI contrast agents effect 
the relaxivity of the water molecules surrounding them. The relaxation of protons to 
concentration of contrast agent relationship can be quantified with the equation 
 
  
 
 
    
      
68,80,81
 where T1,0 is a pre-contrast longitudinal relaxation time and T1 is the 
post-contrast relaxation time, and r1 is the longitudinal relaxivity constant of the contrast 
agent. The relaxivity of Gd-DOTA in saline is similar to the relaxivity of Gd-DTPA used 
in previous studies 3.8 
 
M
-1
ms
-1 128
.  The relaxivity of Gd
3+
 contrast agents tends to 
increase as the molecular weight of the complex increases 
67
.  It is hypothesized the 
relaxivity for both conjugates will exceed the relaxivity of Gd-DOTA alone becoming 
more MRI visible. In order to perform tests necessary to determine bactericidal and MRI 
activity, it is necessary to purify the conjugate. Purification can likely be done by scaling 
up the HPLC protocols using preparatory sized equipment. Scaling up would require a 
larger column, and larger injection assembly on the HPLC. When scaling up the velocity 
of the fluid through the column should be maintained, so the flow rate should be adjusted 
appropriately. 
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If the yield can accurately be determined and is reasonably high (~70%) it is 
unnecessary to separate all the reaction components. It is possible to account for 
unconjugated antimicrobial in tests for biological activity. Sulfo-NHS and EDC need to 
be removed because they could be toxic. Gd-DOTA however cannot be separated from a 
chelated antimicrobial in an MRI image, therefore it would be unknown if the signal was 
coming from Gd-DOTA or a chelated conjugate if delivered in vivo. Furthermore, if the 
two molecules had different relaxivities it would not be possible to calculate 
concentrations accurately. Therefore, it is necessary to separate Gd-DOTA, EDC, and 
Sulfo-NHS from the unchelated DOTA, chelated antimicrobial, unchelated and 
unconjugated antimicrobial before in vivo use.  Since the HPLC shows good separation of 
DOTA-vancomycin it is thought that at least that conjugate can easily be separated from 
all of the other components 
If tests show that antimicrobial and MRI activity are present this molecule could 
be used to visualize the time dependant distribution of these chelates in orthopaedic 
wounds using the methods shown in chapters 2-4. This would be beneficial because an 
active antimicrobial agent might have somewhat different properties from an inert MRI 
contrast agent. Using a conjugated antimicrobial and MRI contrast agent would lead to 
certainty in the location of antimicrobials being used to treat infections clinically. The 
limitation of using the conjugated antimicrobials shown here in a clinical setting would 
be the necessity to get FDA approval, whereas the methods shown in chapters 2-4 use 
FDA approved substances and devices off-label. 
 
5.5 Conclusions 
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It is possible to link DOTA to antimicrobials using EDC chemistry and use the 
DOTA to chelate gadolinium. The separation of DOTA from the conjugate is necessary 
to accurately use this molecule to visualize local drug delivery. 
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Chapter 6: MATHEMATICAL MODELING OF LOCAL DRUG DELIVERY IN 
ORTHOPAEDIC WOUNDS 
 
6.1 Introduction 
Interest in local drug delivery is expanding both in research and industry. Local 
drug delivery vehicles can create a high concentration of drug in a specific region, while 
maintaining much lower levels of therapeutic in other areas of the body. This can focus 
treatment to an affected region, which is important in a variety of applications such as 
tumor treatment 
3
, pain management 
4,5
, tissue engineering 
6
, and infection management 
7
. 
A common local drug delivery vehicles is polymethyl methacrylate (PMMA) bone 
cement, frequently used by surgeons to deliver antimicrobials to the site of orthopaedic 
infections.  
Orthopaedic infection is a common affliction with 1-2% of joint replacement 
surgeries resulting in infection
11,12
. Once established there is a high rate of recurrence 
after surgical intervention, with 10-23% of patients requiring additional intervention 
14,15
. 
Orthopaedic infection is complicated by the presence of biofilm. Microbes attach to the 
surface of an implant and form biofilm, which prevents the host defense system from 
eradicating the microbes 
20,129
. Furthermore, the biofilm not only impedes the transport of 
antimicrobials to the microbes, but also induces phenotypic changes in the bacteria that 
make them more resistant to antimicrobials 
19,22,130
. Biofilm bacteria require 100-1000 
times the antimicrobial concentration required for planktonic bacteria 
22
. Once a biofilm 
has reached maturity sections can fragment and move to other nearby locations. Biofilms 
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also spawn planktonic bacteria, which are small and can travel deeper into the 
surrounding tissue 
19
.  
Orthopaedic infection is normally treated surgically by a two stage revision. In the 
first stage the implant is removed, a debridement of the biofilm and surrounding tissue is 
performed and the area is filled with antimicrobial loaded bone cement (ALBC). After 
the infection has been eradicated the second stage is performed where the implant is 
replaced 
58
. The major concerns for re-infection are an incomplete debridement, biofilm 
debris in the wound and planktonic bacteria, which have not been eradicated by the 
ALBC, in the muscle. Therefore, the goal of antimicrobial treatment is to cover the 
entirety of the debridement surface as well as penetrate into the surrounding muscle with 
antimicrobials of sufficient concentration to kill the microbes. 
In chapters 2-4 a method was outlined where contrast agent, antimicrobial 
surrogate, was imaged using magnetic resonance imaging (MRI) distributing from 
PMMA delivery vehicles placed in vivo in rabbit models. In those chapters antimicrobial 
surrogate delivery from PMMA rods placed in the quadriceps or intramedullary canal of 
the femur were studied. Also antimicrobial surrogate delivery was studied in orthopaedic 
wounds where either: (1) a piece of muscle tissue was removed and replaced with cement 
then the muscle tissue was closed over the top of the delivery vehicle or (2) a piece of 
muscle and cortex of the bone was removed and replaced with cement, but only the skin 
was closed. In these studies  antimicrobial surrogate traveling along regions of high 
permeability such as intermuscular tissue planes and incision lines was repeatedly seen 
99
. 
In order to determine the important transport factors involved in the drug distributions 
seen in the previous chapters, a mathematical model of the behavior will be developed.  
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A model of rabbit anatomy based on diffusion and convection of molecules 
through muscle, bone, intermuscular tissue planes, and wound spaces will be created. It 
will be assumed the major heterogeneous pressure source in this anatomy comes from 
capillary beds disrupted during surgery.  
This research was conducted as a collaboration between Morgan Giers, Alex 
McLaren, Michael Caplan and Ryan McLemore. Morgan Giers and Michael Caplan 
design the models, following the guidance of Alex McLaren who provided several 
physiological phenomena that could be responsible for transport in that region. Morgan 
Giers was also responsible for execution of all models, analysis of all models, and writing 
this chapter. 
 
6.2 Methods and Model Development 
In this chapter Morgan Giers and Michael Caplan use COMSOL Multiphysics 
(COMSOL, Los Angeles, CA) numerical solver to model the transport of an 
antimicrobial in vivo. First a structure of the rabbit anatomy is drawn, then a mesh is 
created. Coefficients are input and COMSOL solves the model for each mesh point, first 
for fluid velocities in the Darcy's Law model, then for concentrations in the convection 
diffusion model (Fig 6.1). 
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Figure 6.1: Schematic of steps in modeling. First a structure is drawn with different 
compartments, then a mesh is created, then the compartments are assigned coefficients 
such as diffusion coefficients. Furthermore, compartments are assigned initial conditions 
and boundary conditions. COMSOL then solves the model for each mesh point at each 
time point desired. First COMSOL will solve for pressure, from that it can use Darcy's 
Law to obtain fluid velocities. From the velocities and diffusion coefficients COMSOL 
can solve the governing equation for mass transport over time. 
 
6.2.1 Governing Equation 
The governing equation in transport phenomena describes three mechanisms 
involved in mass transport: diffusion, convection, and reaction. The equation states that 
the change in drug concentration over time equals the diffusion of the drug into or out of 
the system, the amount of drug leaving or entering the system due to bulk fluid flow and 
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the generation or consumption of the drug within the system. The governing equation is 
given mathematically in equation 6.1 
88
  
  
  
                                                     (eq6.1) 
where C is the concentration, t is time, D is the diffusion coefficient, f is the filtration 
coefficient, v is the velocity of the fluid, and R is a reaction term. In this chapter 
Cartesian coordinates are used in a two dimensional model. 
 
6.2.2 Drug Diffusion (ADC) 
The diffusion coefficients needed to solve the first term of the governing equation 
can be estimated for specific locations within the tissue using an MRI obtained apparent 
diffusion coefficient (ADC) map. The ADC map approximates the diffusion coefficient 
of water in various tissues. In order to calculate ADC maps a series of diffusion weighted 
images (DWI) must be obtained. Diffusion weighted images were obtained in this 
experiment using TR=7.5s, with 30 slices collected. ADC maps can be calculated using a 
series of DWIs taken at different magnetic field strengths (B=0,200,700,1500 s/mm
2
) 
using the following equation 
63
 
        
  
 
                                              (eq6.2) 
where ADC is the apparent diffusion coefficient of water in a voxel, S is signal intensity, 
S0 is the signal intensity when B is zero, and B is the magnetic field strength. The ADC 
map used here was filtered using a median filter to reduce noise; The median filter 
replaces each pixel value with the median value of a group of pixels including itself and 4 
nearest neighboring pixels. Since ADC map values are for water diffusion and not the 
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molecule of interest, the map values should be scaled to reflect the different molecule. 
The diffusion coefficient of the antimicrobial gentamicin in an aqueous buffer is 2x10
-10 
m
2
/s and in alginate, similar to muscle tissue, is 6x10
-12 
m
2
/s 
23
. As such, the ADC map 
values were lowered by multiplying by 4.5x10
-3
 to make the average ADC value closer to 
the value of gentamicin in alginate. 
 
6.2.3 Capillaries and Lymph 
Arterial and lymphatic capillaries can be modeled using Starling's Law which 
states that the flow rate of fluid into and out of capillaries are proportional to the overall 
pressure difference between the inside of the capillary and the interstitium, considering 
both hydrostatic and osmotic pressures. Starling's Law is given in equation 6.3 
88
 
                                                       
(eq6.3) 
where Q is the flow rate, k is the permeability, p is pressure, c stands for capillary, i 
stands for interstitial, and   is osmotic pressure. In this model Morgan Giers and Michael 
Caplan will make the assumption that all pressures inside the capillaries of both the 
lymphatic and arterial capillaries are constant. Morgan Giers and Michael Caplan will 
also assume that the osmotic pressure in the interstitial space is constant. Therefore, 
Starling's Law for both the lymphatic system and arterial reduces to a variable interstitial 
hydrostatic pressure term minus a constant value, an equation suggested by Michael 
Caplan. The two equations can be combined to form the equation 
                                                         
(eq6.4) 
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where   is the constant pressure term. Morgan Giers and Michael Caplan assume that all 
fluid coming from the capillaries is evenly distributed and does not contribute to an 
overall directional flow. Therefore, equation 6.4 is used only as a sink term for any non-
uniform pressure sources. 
 
6.2.4 Flow from Edema 
When capillaries are damaged due to surgery or some other cause they leak 
plasma and cause local edema. Alex McLaren hypothesized that the edema is the major 
source of flow in the anatomical location, muscle tissue, being modeled. In this chapter 
Michael Caplan and Morgan Giers will simplify this to a constant inflow of 1 µL/cm
3
s. 
The pressure field was solved and subsequently used to calculate fluid velocity using 
Darcy's Law, which states that the fluid velocity through a porous medium is proportional 
to the pressure gradient, as shown in equation 6.5 
88
 
      
 
   
                                             
(eq6.5) 
where   is density of the fluid, k is the permeability constant, n is viscosity of the fluid 
and F is a source. This model also assumes the fluid is incompressible and so continuity 
equation 
88
 is true. 
                                                          (eq6.6) 
 
6.2.4 Peclet Number 
  96 
The Peclet Number is a used to compare convection and diffusion within a tissue 
and assess the contributions of each mechanism to the transport of a molecule. The Peclet 
number can be calculated from equation 6.7 
88
 
   
  
 
                                                     (eq6.7) 
where Pe is the Peclet number, L is the characteristic length, v is the fluid velocity, and D 
is the diffusion coefficient. When the Peclet number is high (>10) the transport can be 
considered convection dominant. When the Peclet number is low (<1) the transport can 
be considered diffusion dominant. Regions with Peclet numbers in-between 1 and 10 are 
considered to have significant contributions from both convection and diffusion. 
 
6.2.6 Boundary Conditions 
The skin was treated as a no flux boundary and was modeled with equation 6.8 
88
. 
                                                        (eq6.8) 
All interior boundaries were considered continuous to the next compartment and 
were modeled with the following equation: 
                                                          (eq6.9) 
where C1 is the concentration at the boundary in compartment 1 and C2 is the 
concentration at the boundary in compartment 2. 
 
6.2.7 Mesh Size 
The effect of mesh size on result is analyzed for one model. The mesh is refined 
to three different sized. The concentration map plots are analyzed visually for the three 
mesh sizes at several time points to determine similarity between the results. The results 
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are presented in figure 6.2. Figure 6.2 is a model involving both convection and diffusion. 
The details of the model presented in figure 6.2 are discussed at length in 6.3.2 and this 
model is also shown in figure 6.5. There was very little change in the concentration map 
solution using three different mesh sizes. The edge of figure 6.5 a is not as smooth as 
figure 6.5 b-c, but the overall shape is similar. In order to get a more clearly defined edge 
without causing excessive computational time the mesh size shown in figure 6.5 b was 
used for all models. 
 
  98 
 
Figure 6.2: Convection and diffusion model concentration map in units of mM at five 
hours (a) using the mesh size presented in (d), (b) using the mesh size presented in (e), or 
(c) using the mesh size presented in figure (f). (d-f) are plots of the mesh element area 
used in (a-c). The scale bar for mesh element area is in m
2
.  
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6.3 Results 
 
6.3.1 Does the ADC Map Matter? 
An apparent diffusion coefficient map is obtained using MRI. These map values 
can be imported into COMSOL to generate a discrete diffusion coefficient for every 0.6 
mm
2
 in the model structure. The histogram of the ADC map gives an average value of 
1.2x10
-9
 ±0.4x10
-9
 m
2
/s, which is less than the water self diffusion coefficient, 2.4x10
-9
 
m
2
/s 
131
. Since the model is being created to describe the motion of a small molecule, 
gentamicin (in alginate D=6x10
-12 
m
2
/s 
23
), the ADC map value diffusion coefficients are 
multiplied by 4.5x10
-3
 to make the average value closer to that of gentamicin in alginate 
while maintaining the spatial variation provided by the map. When a diffusion only 
model is run using MRI ADC map values it results in a small circular shaped distribution 
of contrast around a cement rod, as shown in figure 6.2a. Alternatively, a model can be 
run using values input by the user for each compartment, making the diffusion 
coefficients uniform within the compartment. Results from a model with a value of 6x10
-
12
 m
2
/s assigned to the muscle tissue and a value of 1x10
-12
 m
2
/s assigned to the bone are 
shown in figure 6.2b. The diffusion coefficient for the bone is estimated from the 
adjusted diffusion coefficient of bone in the ADC map. The result from a model run with 
uniform diffusion coefficient (Fig 6.2b) is negligibly different from the model run with 
ADC map values (Fig 6.2a). An illustration of the diffusion coefficients given in each of 
these two models is shown in figures 6.2c-d. 
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Figure 6.3: Diffusion only model concentration map in units of mM at five hours (a) 
using ADC Map values as diffusion coefficients or (b) using constant values for diffusion 
coefficients. Model diffusion coefficients (c) using the ADC map or (d) using constant 
values in m
2
/s.  
 
6.3.2 Is Convection or Diffusion Dominant? 
The ADC map overlooks some physiology because of its poor resolution, 0.6 
mm
2
. Features such as intermuscular tissue planes cannot be visualized in that modality, 
but are clearly visible in T1 weighted images, whose resolution is 4 times as great. 
Intramuscular tissue planes are loose, largely acellular, connective tissue between muscle 
groups. In the experimental MRI contrast agent distribution images, shown in chapters 2-
4, contrast agent was often seen preferentially traveling along tissue planes 
99
. A 
compartment is created in the model structure to mimic this anatomical feature. The 
tissue plane compartment is given a diffusion coefficient of 2x10
-10 
m
2
/s, equivalent to 
the gentamicin in an aqueous buffer 
23
, because it is assumed that the actual diffusion 
coefficient of gentamicin in an intermuscular tissue plane cannot exceed that of 
gentamicin in buffer. When a model is run under these conditions some gentamicin 
travels along the tissue plane, but substantially more travels into the tissue (Fig 6.3). 
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Figure 6.4: Model concentration map in units of mM at one hour in a diffusion only 
system, where the diffusion coefficients are increased in the intramuscular tissue plane. 
 
In order to capture the preference seen for contrast agent traveling along tissue 
planes and incision tracks, as discussed and illustrated in chapters 2-4, convection is 
added to the model. A flow source with a constant value of 1 µL/cm
3
s is added around 
the implant to model edema from damaged capillaries resulting from device implantation. 
A flow sink term of -10
-12
(pi-101325) Pa is applied to all other compartments, meant to 
represent capillary and lymphatic uptake. The sources and sinks create a pressure 
gradient from the source compartment around the delivery vehicle to the surrounding 
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tissue and rest of the leg, as shown in figure 6.4a. Different permeabilities were applied to 
each tissue. The permeability of the muscle is lower than the tissue plane. Unless 
otherwise noted the diffusion coefficients and permeabilities for this and all subsequent 
models are given in table 6.1. The tissue plane is an area of low resistance to flow, high 
permeability, and has a higher fluid velocity than the surrounding tissues, as shown in 
figure 6.4b. When the resulting contrast distribution is plotted there is a large preference 
for contrast traveling in the tissue plane (Fig 6.4). The same model was run for a coronal 
view of a leg. In this model the diffusion coefficient in the vertical direction is 6x10
-11
 
m
2
/s and in the horizontal direction is 6x10
-12
 m
2
/s because the diffusion coefficients 
along the direction of muscle fiber alignment is higher than perpendicular to them (Fig 
6.5). In this model contrast agent also travels along the tissue plane. 
 
Table 6.1: Model concentration map at one hour in a diffusion only system, where the 
diffusion coefficients are increased in the intramuscular tissue plane 
 
Diffusion Coefficient (m
2
/s) Permeability (m
2
) 
Muscle 6x10
-12
 2x10
-17
 
Bone 1x10
-12
 1x10
-19
 
Tissue Planes 2x10
-10
 2x10
-15
 
Bone Cement 1x10
-14
 1x10
-20
 
source 2x10
-10
 2x10
-15
 
biofilm 7x10
-10
 2x10
-17
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Figure 6.5: Solution to model with both convection and diffusion at five hours where (a) 
is the pressure field in Pascal
 
(b) is the velocity solution in m/s and
 
(c) is the 
concentration solution in mM. 
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Figure 6.6: Solution to model with both convection and diffusion at five hours where (a) 
is the pressure field in Pascal
 
(b) is the velocity solution in m/s and
 
(c) is the 
concentration solution in mM. 
 
In order to assess if the transport in the musculoskeletal system is primarily 
dominated by convection or diffusion, two models are created with a all diffusion 
coefficient decreased by an order of magnitude or increased by an order of magnitude. 
The resulting concentration distributions (Fig 6.6a-b) show more gentamicin penetrates 
muscle when the diffusion coefficients are high with respect to the permeability. A plot 
of the Peclet numbers for each of these models is given in figure 6.6c-d. When the Peclet 
number is high (>10) the transport can be considered convection dominant. When the 
Peclet number is low (<1) the transport can be considered diffusion dominant. Regions 
with Peclet numbers in-between 1 and 10 are considered to have significant contributions 
from both convection and diffusion. In the model with lowered diffusion coefficients 
there is a region in and near the tissue plane that is controlled by both convection and 
diffusion, but the majority of the transport in the leg is controlled by convection (Fig 
6.6c). In the model with increased diffusion coefficients the region near the implant is 
controlled by diffusion, but there is a region in the middle of the leg where convection 
plays a role (Fig 6.6d). It seems that within a 2 order of magnitude range there is always 
some role played by both convection and diffusion in the transport of gentamicin. This 
indicates that both mechanisms of transport should be included in the model. 
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Figure 6.7: Concentration map (in mM) solutions for two models with the same 
permeabilities and different diffusion coefficients at five hours where model (a) has 
diffusion coefficients decreased by one order of magnitude from figure 6.4 and (b) has 
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diffusion coefficients increased by one order of magnitude from figure 6.4. (c) and (d) are 
the associated Peclet number plots for (a) and (b) respectively.  
 
Since the tissue planes in rabbits are so loosely connected they can easily be 
separated during a surgical procedure. The variable separation between muscle groups 
could lead to a range of permeabilities in the tissue plane. Figure 6.7 shows models where 
the permeability of the tissue plane only has been decreased by an order of magnitude 
(Fig 6.5a) or increased by an order of magnitude (Fig 6.7b). The two models have 
negligibly different distributions. 
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Figure 6.8: Model with increased permeability in intramuscular tissue plane at 1 hour 
where model (a) has k=2x10
-15 
m
2 
and (b) has k=2x10
-13 
m
2
. 
 
6.3.3 What do Different Materials Look Like? 
There is a large variety of materials that are explored as delivery vehicles in 
antimicrobial release as well as other applications. It is important to consider how 
changing material properties affect in vivo drug distribution. To explore changing 
material properties a model with lower diffusion coefficient (D=1x10
-16
 m
2
/s) and 
permeability (k=1x10
-22 
m
2
) is created. A model with higher diffusion coefficient 
(D=1x10
-12
 m
2
/s), similar to the diffusion coefficient of biodegradable polyanhydride 
materials, and permeability (k=1x10
-18 
m
2
) was also created. The spread on both models 
is similar, but the model with the faster releasing device has about 100 times higher 
concentration (Fig 6.8a-b). When the total molar mass left in the delivery vehicle is 
graphed over time the difference between these two vehicles is dramatic. The faster 
releasing vehicle releases over half its load in the first 19 hrs, while the slowly releasing 
vehicle retains almost all its load over that period of time (Fig 6.8c-d). 
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Figure 6.9: Model with (a) decreased diffusion coefficient (D=1x10
-16
 m
2
/s) and 
permeability (k=1x10
-22 
m
2
) of the drug delivery vehicle at five hours and (b) increased 
diffusion coefficient (D=1x10
-12
 m
2
/s) and permeability (k=1x10
-18 
m
2
) of the drug 
delivery vehicle at five hours. The concentration units are in mM. (c) and (d) are the total 
mass left in implants, from (a) and (b) respectively, as a function of time. 
 
6.3.4 What do Different Wound Types Look Like? 
  110 
In order to assess how universal the model is for different types of surgical 
procedures, models with different geometries are created and given the same parameters 
as the previous model (Fig 6.4). The models are compared to wounds created in chapters 
2-4. Briefly, an intramuscular rod, an intrafemoral rod, a partial thickness muscle 
removal, and a full thickness muscle and bone removal model are shown. In each 
structure, figures 6.9 a, c, and d, there is a region surrounding the implant that is assumed 
to be damaged tissue and is given a source term. In figure 6.9d a region of less damaged 
tissue is modeled extending from the skin to the implant, representing an incision line 
that remains unclosed. It is assumed that the vasculature is less damaged by an incision 
than in the removed muscle section, so the incision compartment is assigned a flow 
source (10
-5
 kg/m
3
s) two orders of magnitude less than the tissue adjacent to the implant 
(10
-3
 kg/m
3
s). In the intramedullary model there is no region of damaged vasculature. The 
modeled distributions have similarities to their experimental counterparts. In figure 6.9c 
there is some contrast entering the tissue plane as seen in the experimental image in 
figure 6.9g, but the overall distribution is larger in the model than in the experimental 
image. In figure 6.9d the contrast travels around the tissue plane, but contrast in figure 
6.9h is not seen in that region. Also in figure 6.9d more contrast travels towards the back 
of the leg than the front and in figure 6.9h the opposite occurs. Each of these have 
different surgeries with different degrees of tissue damage. This model is not entirely 
universal and there are aspects that are not captured by the current parameters.  
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Figure 6.10: Model of 4 different wound types a five hours (a) intramuscular rod, (b) 
intrafemoral rod, (c) partial thickness muscle removal, and (d) full thickness muscle and 
bone removal model. Also shown in (e-h) is the MRI distribution images at 5.5 hours for 
model (a-d) respectively. All parameters are entered for each model as given in table 1. 
Model (d) has a lower pressure source term than the wound area included to model the 
open incision sight that has less damaged tissue than the wound. The incision area 
extends from the wound area to the subcutaneous tissue plane. Both scale bars are in mM. 
 
6.4 Discussion 
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The model showed that ADC maps are not necessary to appropriately model 
diffusion in muscle tissue. ADC maps might be more practical and necessary in models 
of other anatomies, where the diffusion coefficients of the important features are captured 
by the ADC map and the structure is more difficult to draw. Obtaining and using an ADC 
map is difficult, time consuming, and costly, so if the results are not compromised there 
are many benefits to using a per compartment diffusion coefficient rather than an ADC 
map.  
Diffusion only models did not capture all the mechanisms responsible for the 
distributions seen in experimental images so moderate levels of convection could easily 
be responsible as a transport mechanism for an antimicrobial in a wound. The 
convections is important to the anisotropy of distribution. Areas of high permeability 
offer low resistance to flow and easily carry drugs along those paths. Areas of high 
permeability in the rabbit included tissue planes which are more rigid in human patients 
and are unlikely to display the same behavior; however, these tissue planes can be 
generalized for any high permeability region, such as incision lines. Incisions are not 
generally left open in humans, but even closed incisions are likely to have a slightly 
greater permeability. Most importantly those high permeability features reveled the most 
about underlying transport mechanisms. Even if a surgeon normally closes a high 
permeability incision, that region could just be modeled with a smaller permeability and 
the other transport mechanisms should be otherwise the same. 
COMSOL does not converge well when there are regions where the gradients are 
very steep. Regions with steep gradients include regions that are very small, but contain 
different transport properties from its neighbors. In this model the wound region was very 
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large so that COMSOL could more easily solve it. Realistically the region might be 
smaller and the effects less dramatic, particularly in the intermuscular rod model. 
An in vivo model can be used to explore new material options. There are many 
mathematical models describing how drugs elute from local delivery vehicles, but few 
describing how drugs move in vivo from a local delivery source. There are some in vivo 
models of drug delivery to tumor sights 
77,79,132-135
. Modeling the in vivo parameters can 
create a framework where a solution, such as different material parameters, can be 
engineered based on the desired result. For instance, if it was desired to cover a larger 
region of the leg for a specified period of time, different loading amounts and material 
parameters could be explored in the model before choosing a material to test in an 
experimental animal model.  
Although a single model cannot be applied for all surgical situations, it can help 
in describing general behaviors. The experimental models from chapters 2-4 have shown 
a large animal to animal variability. The animal to animal variability could stem from 
parameters like different wound sizes, different placements of the implant, and different 
degrees of separation in the tissue planes. It is unlikely these models will be able to 
predict precise locations of antimicrobial distribution, but these models can help us 
explain the mechanisms seen in the MRI images and suggest how changing surgical or 
material parameters can effect distributions in a general way. 
 
6.5 Conclusions 
The model showed that ADC maps are not necessary to appropriately model 
diffusion in tissue. Diffusion only models do not capture all the mechanisms responsible 
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for the distributions seen in experimental images so moderate levels of convection could 
easily be responsible as a transport mechanism for gentamicin in a wound. An in vivo 
model can be used to explore new material options. Although a single model cannot be 
applied for all surgical situations, it can help in describing general behaviors.  
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Chapter 7: CONCLUSIONS AND FUTURE WORK 
 
In this work Morgan Giers, Alex McLaren, Chris Estes, Kenneth Schmidt, Ryan 
McLemore, and Michael Caplan developed a new method for visualizing the distribution 
of antimicrobial surrogate from local delivery vehicles in orthopaedic wounds. This team 
found contrast agent distribution could be seen in near real time 
99
. Also it was possible to 
perform quantitative analysis on those images. The strengths and weaknesses of the 
method and detailed the image processing required for quantification of drug distribution 
was shown
105
. The method was used in minimally invasive procedures, IMR and IOR, as 
well as complex wound environments, PTM and FTMB, and were able to see different 
behaviors based on the type of wound 
106
. It was repeatedly seen that contrast agent 
remained mostly within the local wound space and traveled furthest down paths of least 
resistance to flow. A mathematical model was created of the hypothesized important 
factors affecting the drug distribution in tissue. Morgan Giers and Michael Caplan with 
input from Alex McLaren and Ryan McLemore were able to model similar behaviors to 
that seen in vivo by assuming there was edematous flow from the damaged tissue and 
using a combination of convection and diffusion transport mechanisms. 
 
7.1 Spatiotemporal Distribution of Contrast Agents Delivered to Orthopaedic Wounds 
In order to adequately treat an infection, high concentrations of antimicrobial 
must be both achieved and maintained. Bactericidal effect is a function of both 
concentration and time 
136
. In the work outlined thus far significant differences in volume 
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or total mass of antimicrobial surrogate were not seen in the images as a function of time. 
The lack of significant change over time is likely due to the short period of time over 
which the images were acquired. Images were acquired over times less than 6 hours after 
implantation of the delivery vehicle when the expected length of treatment is several days 
to weeks long 
2
. For this reason this group is interested in looking at the distribution at 
longer time points. The preliminary data from one rabbit shows nearly all the contrast in 
concentrations above the visible range is no longer present at ~3 days (Fig 7.1). More 
replicates of longer the longer study are currently underway. The data from this one 
animal, however, fits with the previous short time period values from previous animals 
(Fig 7.2). In figure 7.2 the total milligrams of contrast calculated in the control images are 
also provided to show that at ~3 days the image with contrast approaches the same mass 
as the control images. 
 
Figure 7.11: 3D reconstruction of Gd-DTPA distribution and bone cement with 2g of Gd-
DTPA and 8 g xylitol porogen per 60 grams of PMMA at (a) 1hour (b) 1 day and (c) 5 
days.  
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Figure 7.2: Graph of total milligrams of contrast in the image of an individual rabbit over 
time compared with average mass of contrast agents for the same wounds in multiple 
other animals at 5.5 hrs. 
 
7.2 Quantification of Differences Between Active Therapeutic Agent and Inert Molecule 
Distributions 
In order to use the methods outlined in chapters 2-4 as a clinical tool therapeutic 
agents would need to be present. These therapeutics could be present as conjugated 
antimicrobials and MRI contrast agents, as outlined in chapter 5, or simply co-delivered 
with Gd-DTPA. Co-delivery of antimicrobials and Gd-DTPA would be a more versatile 
method since co-delivery would avoid complex chemical synthesis of new molecules and 
could simply utilize currently available pharmaceuticals. Ideally any combination of 
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antimicrobials to be co-delivered with Gd-DTPA in order to treat a specific infection on a 
patient specific basis. A patient could then receive an MRI within the first 24 hours to 
confirm if the surgical intervention is likely working. The major assumption of a co-
delivery procedure would be that an inert contrast agent and active antimicrobial have the 
same transport and one is analogous for the other. So by visualizing the Gd-DTPA with 
MRI it could be assumed that the therapeutic was in the same locations. Theoretically the 
transport of most antimicrobial molecules should be similar to Gd-DTPA since they are 
all low molecular weight, hydrophilic compounds; however, providing evidence that the 
contrast agents and antimicrobials behave the same would validate the method. 
Arguments as to why they would not behave the same are discussed later in this section. 
The behavior of the two different types of molecules can be compared both in their 
delivery from the delivery vehicle and their distribution in actual tissue.  
In order to determine if an antimicrobial and Gd-DTPA deliver the same from the 
bone cement a simple in vitro elusion profile could be obtained. The elusion profile can 
be measured by placing a sample of the cement containing both MR and antimicrobial 
agents in a relatively large volume of phosphate buffered saline. The fluid can be replace 
at certain intervals and the concentrations of each agent in that fluid measured. If they are 
the same this would indicate that the two types of molecules deliver similarly from the 
vehicle. For the antibiotic vancomycin the concentrations can be determined using 
HPLC. A standardized curve can be obtained for the area under the absorbance curve 
(AUC) for a series of known concentrations (Fig 7.3). An equation can then be obtained 
describing that relationship and applied to unknown concentrations of samples from the 
in vitro elution study. A plot of total mass released over time can be constructed (Fig 
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7.4). The vancomycin elution profile can be compared to the elution profile of Gd-DTPA. 
Gd-DTPA has a much lower absorbance than vancomycin and is difficult to obtain 
concentrations using HPLC; however the concentrations of Gd-DTPA can be obtained 
from relaxivity measurements of the fluid using NMR.  
In addition to delivering the same from the cement the MR and antimicrobial 
agents must also distribute the same in the tissue. It is possible that one agent could bind 
to macromolecules in the body, such as those present in serum, or bacteria, where the 
other agent does not. Differences in binding could mean that even if the agents would 
distribute similarly based on diffusion and convection, their distribution might differ 
because of preferential binding. To demonstrate potential differences in distribution due 
to binding a model was created where a low flow rate source was placed in the center of a 
circle and two different diffusion coefficients were given to two molecules within that 
space. All other parameters of the model are the same as the parameters demonstrated in 
chapter 6. One molecule was given a diffusion coefficient of 6x10
-12
 m
2
/s (the diffusion 
coefficient of gentamicin in alginate)
23
 and the other a diffusion coefficient of 12x10
-12
 
m
2
/s (twice as high as gentamicin ~Gd-DTPA). When the simulation is run with both 
convection and diffusion there is very little difference in the concentration distributions 
(Fig 7.5a,b); however, when a small section near the source is modeled as reacting with 
one of the molecules, such as the molecules binding to bacteria, the distribution of one of 
the molecules is different from the other (Fig 7.5c,d). This is model is not based on 
realistic parameters, it is simply meant to demonstrate a potential reason for the 
distribution of antimicrobials and Gd-DPTA to differ significantly. To obtain realistic 
parameters in vitro agar gels could be used to image the distribution of a fluorescent 
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antimicrobial, such a tetracycline 
137
, and Gd-DTPA over time with and without the 
presence of bacteria.  
For a more complex but clinically relevant model, Gd-DTPA and a fluorescent 
antimicrobial could be co-delivered in a rabbit model using the same surgical procedures 
described in chapters 2-4. Then one of two procedures could be used to determine if the 
antimicrobial is in the same location as the Gd-DTPA seen in the MR images. First a 
series of biopsies could be taken near the implant the and the concentrations of 
antimicrobials in those biopsies could be determined. This method is limited in spatial 
resolution to the number of biopsies taken and is very time consuming, however is 
comparable to the methods used to obtain antimicrobial distributions in vivo prior to the 
development of the imaging method. Alternatively, the animal could be euthanized and 
perfused with fixative. Then the tissue could be embedded in resin and tissue slices could 
be obtained. The slices could be imaged to determine the distribution of the fluorescent 
antimicrobial. Histological slices are limited in temporal resolution as the animal must be 
euthanized. 
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Figure 7.3: Concentration vs. area under the absorbance curve for vancomycin run on an 
HPLC. 
 
 
Figure 7.4: Elution profile of vancomycin from bone cement. 
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Figure 7.5: COMSOL model at 19 hours of (a) gentamicin distribution (b) Gd-DTPA 
distribution (c) gentamicin distribution in the presence of a region where gentamicin is 
bound and (d) Gd-DTPA distribution in the presence of a region where gentamicin is 
bound. 
 
7.3 Imaging an Active Antimicrobial Agent 
In order to visualize an active antimicrobial agent and not a surrogate one of the 
conjugates shown in chapter 5 could be used. Before using this agent the chelated 
conjugate would need to be purified and several other tests performed. I would need to 
test for biological and MRI activity. It is hypothesized that both the biological activity 
and MRI activity would be maintained because of previous studies by other groups 
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67,122,123,127
. If a completely pure conjugate cannot be obtained this team could use a high 
yield mixture of the product as long as the yield is sufficient (~70) and little to no Gd-
DOTA is present in the sample. It would also still be possible to determine the biological 
and MR activity using that unpurified sample. The same methods used in chapter 2-4 
could be applied using a conjugated antimicrobial in place of an MRI contrast agent 
alone. The concentration calculation would be modified to use a relaxivity constant 
unique to the chelated antimicrobial. 
 
7.4 Imaging Drug Distribution in the Presence of an Active Infection 
Previously drugs distributing into orthopaedic wounds were imaged, but drug 
distribution in the presence of an active infection where biofilm was present has not been 
investigated. Biofilm has transport properties unique from normal tissue. The different 
transport properties could affect the distribution of antimicrobials. To study the changes 
in distribution when biofilm is present bone cement seeded with bacteria could be 
implanted into one of the previously used surgical wound models in a rabbit, partial 
thickness muscle removal model or full thickness muscle and bone removal model. Once 
an infection has been established a surgery could be performed to replace the bone 
cement with ABLC containing either the conjugated antimicrobial or a mixture of Gd-
DTPA and antimicrobial. If a fluorescent antimicrobial were used histology could be 
performed similar to what was described in section 7.2. Additional histology could be 
performed to stain for biofilm as well, which would allow for visualization of the 
antimicrobial within the biofilm. Alternatively, predictions of prognosis could be made 
based on the MR images, the ABLC could be allowed to treat the infection, and the actual 
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recovery rate could be determined similar to other clinical outcome studies. A prediction 
study could be used to evaluate the usefulness of the method as a clinical diagnostic tool. 
Such a study would, however, require a large number of replicates. 
In order to determine the transport properties within biofilm, several simple in 
vitro experiments could be performed. A fluorescent antimicrobial, such as tetracycline, 
could be applied to a well in the center of a biofilm and the distance of the antimicrobial 
from the well over time could be measured using simple fluorescent microscopy or 
possibly photography. The distance traveled over time would yield a diffusion coefficient 
of that antimicrobial in the biofilm. Similar experiments have been performed using more 
expensive MRI images for a phototropic biofilm 
138
. Those authors posited that the 
diffusion coefficient they obtained, which was unrealistically fast, also incorporated 
convection. In order to obtain a permeability constant back pressure could be applied to 
the central well and images could be taken to track the progress of the antimicrobial. 
These data could be fit with an equation that included convection and diffusion in order 
to obtain the permeability constant.  
The realistic transport parameters obtained from the in vitro experiments could be 
used as parameters in mathematical models of antimicrobial distribution in an infected 
animal. The models could be compared to the MR images of contrast distribution in an 
infected. 
 
7.5 Mathematical Modeling of Local Drug Delivery Vehicles 
It is also of interest to model drug release kinetics from PMMA bone cement. 
PMMA itself is not permeable to water. So three steps are involved in the delivery of 
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drugs from a PMMA delivery vehicle. Water must hydrate the pores near the 
antimicrobial or other porogen. Then the solute must dissolve. Finally, the solute must 
leave the cement. Modeling of these parameters could help to determine what the rate 
limiting steps in the elution process are and guide methods of tailoring cement 
compositions to obtain the desired release characteristics based on interconnectivity or 
pores, pore size, and solute loading. The modeled data could be compared to elution 
profiles obtained under near infinite sink conditions.  
 
7.6 Conclusion 
This dissertation represents a body of work that establishes a new method for 
characterization local drug delivery depots and quantification of distributions in vivo. 
This work demonstrates a synergy between drug delivery, imaging, and modeling that 
produces a comprehensive method for studying drug delivery problems in vivo. 
In this work local drug delivery was visualized in minimally wounded tissue as 
well as large orthopaedic surgical wounds using MRI. It was found that it was possible to 
visualize contrast agent distribution in near real time using a non invasive technique that 
is translatable to human patients. It was possible to quantify the distribution and use it to 
draw conclusions about local drug delivery in musculoskeletal sites. It was found that the 
antimicrobial surrogate did not distribute far from the local delivery vehicle, but 
remained mostly within the wound space. Antimicrobial were repeatedly visualized 
distributing down paths of least resistance to fluid flow. A mathematical modeled of this 
behavior found that fluid flowing from the wound site, such as edema, could be 
responsible for the distributions seen in the images. It was also found that drug 
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distribution is likely a convective and diffusive process. These methods could be used as 
a clinical tool to evaluate patient treatment on a patient specific basis.  
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A.1 UnstacktifT1wandT1 
%This is an IO file that reads in a stack of T1 maps and T1 weighted images 
%as an hdr and exports unstacked tif images and saves them.   
%Prior to exporting the images it processes them to remove noise. 
originalimage=readdata3d;                                                     %GUI to import hdr 
downloadable from the MATLAB website. 
originalimaget1w=readdata3d; 
originalimage=double(originalimage);                                   %Changes matrix type to 
double. 
[xo yo zo]=size(originalimage);                                             %Finds the size of the matrix 
timepoint=input('input the timepoint chosen: ')                      %Choose what the timepoint 
was so that it is entered into the filename 
originalimage=originalimage(:,:,3:5:end-2);                          %Indexes out all the extra 
slices containing standard deviation, etc. to leave only the actual map slices 
[x y z]=size(originalimage); 
[x1 y1 z1]=size(originalimaget1w); 
originalimaget1w=originalimaget1w(:,:,1:z);                         %Shortens matrix to only 
include the first set of images taken at the same TR value 
top=6000;                                                                                %A cut off point where 
above that value in the map images most pixels are noise 
topw=1500000;                                                                       %A cut off point where 
above that value in the weighted images most pixels are noise 
[originalimagecutt1w]=cutoff(originalimaget1w,topw);     
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[originalimagecut]=cutoff(originalimage,top);                      %Cuts off above the value 
chosen in top.  Anything above top is made equal to top. 
disp('I am restoring now') 
[filteredlinear]=medianfilter(originalimagecut,5);                 %Cleans some noise from the 
image using a median filter 
[filteredlineart1w]=medianfilter(originalimaget1w,9);          %Prepares image for 
masking program   
disp('I am masking now') 
[mask]=masking(filteredlineart1w);                                       %Creates binary mask of 
where there are legs 
cleaned=double(filteredlinear.*mask);                                   %Removes all noise from 
outside of the legs in the map image 
cleanedt1w=double(originalimagecutt1w.*mask);                %Removes all noise from 
outside of the legs in the weighted image 
cleanedt1w=cleanedt1w*65536/1500000;                             %Adjusts scale to a value of 
65536/2^16 (bitdepth of 16) which is what a tif is out of.  If you do not do this it will turn 
all pixels above 2^16 into 2^16. 
cleaned=uint16(cleaned);                                                       %Makes sure the matrix is 
recognized as uint16 
cleanedt1w=uint16(cleanedt1w); 
for k=1:z1 
filenamet1w = sprintf('w_%d_%d.tif',timepoint,k);               %Creates a filename based 
on the timepoint and the slice number 
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imwrite(cleanedt1w(:,:,k),filenamet1w);                                %Exports images to the 
current directory folder 
end 
 
A.2 Cutoff 
function [Topcleaned]=cutoff(image,cutoffpoint) 
%This program turns any value in a matrix above the specified "cutoffpoint" 
%into the value of the cutoff point. 
[x y numslice]=size(image);                                                   %Determines the size of the 
matrix imported 
Topcleaned=zeros(x,y,numslice);                                           %Creates a matrix of zeros 
with the dimensions of the imported matrix 
image(isnan(image))=0;                                                         %Replaces any non real 
numbers in the imported matrix with a value of zero 
for i=1:x 
    for j=1:y 
        for k=1:numslice 
             if image(i,j,k)>cutoffpoint 
                Topcleaned(i,j,k)=cutoffpoint;                               %Replaces any values above 
the cutoff point with the value of the cutoff point in the new matrix Topcleaned 
             else 
                Topcleaned(i,j,k)=image(i,j,k);                               %Any other values remain 
the same as their original value in the imported matrix 
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             end 
        end 
    end 
end 
 
A.3 Medianfilter 
function [filteredlinear]=medianfilter(originalimage,degree) 
%This program uses a median filter of the specified degree to remove noise 
%in an image.  A median filter takes the median value from a certain number 
%of surrounding pixels and itself.  The degree specifies the number of 
%surounding pixels you want included (the default is 5).  A degree of 5 
%will take the 4 nearest neighbor pixels and itself. 
while nargin==1                                                                     %If no degree is specified use 
a degree of 5 
    degree=5; 
end 
[ x y z]=size(originalimage);                                                  %Find the dimensions of the 
imported matrix 
filteredlinear=zeros(x,y,z);                                                     %Specifies a matrix of zeros 
the size of the imported matrix 
for k=1:z                                                                                 %Indexes through each slice 
of the image stack and filters.  The filtered image is stored in the new matrix 
filteredlinear. 
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    filteredlinear(:,:,k)=ordfilt2(originalimage(:,:,k),degree,ones(3,3)); 
end 
 
A.4 Masking 
function [mask]=masking(originalimage)  
%This program turns an image binary and makes a mask. 
[x y numslice]=size(originalimage);                                       %Finds dimension of the 
imported matrix 
normalized=originalimage./max(max(max(originalimage)));%Adjusts matrix to be out of 
a value of 1 
Opened=zeros(x,y,numslice);                                                %Creates matrix of zeros 
Closed=zeros(x,y,numslice);  
mask=zeros(x,y,numslice); 
Binary=zeros(x,y,numslice); 
SE=strel('disk',3);                                                                   %Creates a structure element 
that is a disk shape with a radius of 3.  This is used in the following convolution 
functions. 
SE2=strel('disk',3);  
for k=1:numslice                                                                    %Indexes through each slice 
for the following functions that are meant for 2D images 
    Opened(:,:,k)=imopen(normalized(:,:,k),SE);                    %Morphologically opens the 
image. 
    Closed(:,:,k)=imclose(Opened(:,:,k),SE2);   
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    Binary(:,:,k)=im2bw(Closed(:,:,k),0.02);                           %Turns the image binary 
around a certain value.  Values above change to a 1, values bellow change to a 0. 
    mask(:,:,k)=imfill(Binary(:,:,k),'holes') ;                            %Fills holes in the image.  If 
there are a group of 0's surrounded by 1's it will fill the 0 spots with 1's.                         
    mask(:,:,k)=bwareaopen(mask(:,:,k),100);                         %This removes 1's from the 
binary image if they are not connected a minimum of 100 pixels. 
end 
 
A.5 T10estimatorwithimport 
%This program works with the program T10estimator to import an image, 
%process the image, and find the average and standard deviation of the 
%histogram of that image, where the cement and contrast pixels have been 
%removed. This can be correlated to the pre-contrast T1 value. 
clear all 
originalimage=readdata3d;                                                     %GUI to import hdr 
originalimaget1w=readdata3d; 
originalimage=double(originalimage); 
[xo yo zo]=size(originalimage); 
originalimage=originalimage(:,:,3:5:end-2);                          %Indexes out all the extra 
slices containing standard deviation, etc. to leave only the actual map slices 
[x y z]=size(originalimage); 
originalimaget1w=originalimaget1w(:,:,1:z);                         %Shortens matrix to only 
include the first set of TR values 
  148 
top=6000;                                                                                %A cut off point where 
above that value most T1 map pixels are noise 
topw=1500000;                                                                       %A cut off point where 
above that value most T1 weighted pixels are noise 
[originalimagecutt1w]=cutoff(originalimaget1w,topw);     
[originalimagecut]=cutoff(originalimage,top);                      %Cuts off above the value 
chosen in top.  Anything above top is made equal to top. 
disp('I am restoring now') 
[filteredlinear]=medianfilter(originalimagecut,5);                 %Cleans some noise from the 
image 
[filteredlineart1w]=medianfilter(originalimaget1w,9);          %Prepares image for 
masking program   
disp('I am masking now') 
[mask]=masking(filteredlineart1w);                                       %Creates binary mask of 
where there are legs 
cleaned=double(filteredlinear.*mask);                                   %Removes all noise from 
outside of the legs 
[frequencyalldim,Intensity,mean,standarddev]=T10estimator(cleaned,100);    %Creates a 
symmetrical histogram of the image based on the top half of the histogram to remove 
contrast and cement pixels, then finds the average and standard deviation of the 
histogram. 
disp('mean= ') 
disp(mean) 
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disp('standard deviation= ') 
disp(standarddev) 
 
A.6 T10estimator 
function [frequencyalldim,Intensity,mean,standarddev]=T10estimator(matrixname,b) 
%Creates a symmetrical histogram of the image based on the top half of the 
%histogram to remove contrast and cement pixels, then finds the average and 
%standard deviation of the histogram. 
%b is the number of bins desired 
[x y numslice]=size(matrixname); 
matrixname=cutoff(matrixname,6000);                                 %Cuts off all matrix values 
above 6000. 
top=max(max(max(matrixname)));                                        %Finds the maximum value 
in the matrix 
Intens1=zeros(b); 
frequency=zeros(b,numslice); 
for l=1:numslice 
    [frequency(:,l) Intens1]=imhist(matrixname(:,:,l)./top,b); %Calculates a histogram for 
each image slice. The scale must be from 0 to 1 so all matrix values are divided by the 
top matrix value. 
end 
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frequencyalldim=sum(frequency,2);                                      %Sums the histograms for all 
slices to get the 3D image histogram 
frequencyalldim(1,1)=0; 
frequencyalldim(b,1)=0; 
Intensity=Intens1.*top;                                                           %Finds the intensity values 
of the original image scale. 
maximumfrequency=max(max(frequencyalldim));               %Finds peak histogram value 
[N,M]=find(frequencyalldim==maximumfrequency);           %Finds location of peak 
histogram value 
frequencybackward=flipud(frequencyalldim);                       %Mirrors histogram about 
the peak histogram value 
if N<b/2                                                                                  %If the peak is in the first 
half of the histogram copies the last part of the histogram to make symmetric and cuts off 
last part of histogram 
   frequencyalldim(1:N,1)=frequencybackward((b-2*N+2):(b-N+1),1);  
   frequencyalldim((2*N):end)=0; 
elseif N>b/2                                                                            %If the peak is in the second 
half of the histogram copies the last part of the histogram to make symmetric then adds 
zeros to any value before the histogram starts 
    frequencyalldim((2*N-b):(N-1),1)=frequencybackward(1:(b-N),1);  
    frequencyalldim(1:(2*N-b-1))=0; 
else 
    frequencyalldim(1:(N-1),1)=frequencybackward(1:(b-N-1),1);  
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end 
mean=Intensity(N,1);                                                             %Finds the mean of the 
symmetric histogram, which is the peak value 
SS=frequencyalldim.*(Intensity-mean).^2;                           %Sum of Squares 
standarddev=sqrt((1/sum(sum(frequencyalldim)))*sum(sum(SS))); %Finds the standard 
deviation of the histogram 
 
A.7 Mimicsimportandmapmaker 
%This program imports a segmented contrast area mask from mimics, makes a 
%concentration map and a movie.  Before running change the filename, move 
%the mask images into the directory folder, and remove 0z from before single 
%digit numbers.  Afterword save maskdrug, 
%maskdrugrecuded Cpicture, C,  
%Cement, M, and the movie in the directory. 
filename='3_30_12_time31_w_left contrast tres 2145+0000'; %Enter the filenames for 
the mask you are importing. 
T10estimate=2788;                                                                 %Enter value of T10 
calculated from T10estimator or use an average value from several animals, such as 2817 
ms. 
originalimage=readdata3d;                                                     %Import T1 map using GUI 
originalimaget1w=readdata3d;                                               %Import T1 weighted image 
using GUI 
  152 
originalimage=originalimage(:,:,3:5:(end-2));                       %This indexes out the extra 
slices containing standard deviation, etc. and leaves only the actual map slices. 
[x y z]=size(originalimage);                                                   %Finds the dimensions of the 
T1 map after removing extra slices. 
originalimaget1w=originalimaget1w(:,:,1:z);                        %The T1 weighted hdr comes 
as a series of T1 weighted scans with different TR values.  This takes only the set from 
the first TR value.  This should match the dimensions of the T1 map. 
disp('I am restoring now')                                                       %Displays the single quoted 
words in the command window. 
[filteredlinear]=medianfilter(originalimage,5);                      %Runs the noise reducing 
filtering program medianfilter on the T1 map. 
[filteredlineart1w]=medianfilter(originalimaget1w,9);          %Runs the noise reducing 
filtering program medianfilter on the T1 weighted.  This is meant to prepare this image 
for transform into a mask. 
disp('I am masking now') 
[mask]=masking(filteredlineart1w);                                      %This runs the program 
masking that creates a binary mask on the legs.  1's indicate that it is a point inside the 
legs, 0's indicate it is a point outside the legs. 
cleaned=double(filteredlinear.*mask);                                   %multiplying the reduced 
noise T1 map by the binary mask removes all noise outside the legs. 
cleanedt1w=originalimaget1w.*mask;                                              
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[maskdrug]=restack(filename,originalimaget1w);                 %This runs a program that 
imports a stack of masked images from mimics.  You must put the images in the 
directory folder. 
reducedmask=reducemask(mask,3);                                      %Reduces the outside of the 
mask of the leg by 3 pixels. 
maskdrugreduced=maskdrug.*reducedmask;                         %Gets rid of an edge effect 
on the segmented region. 
[Cpicture,C,Cement]=concentration(maskdrugreduced,1,cleaned,cleanedt1w,T10estimate
);          %This creates a concentration map of the image 
[M]=movierabbitconcentration(maskdrug,maskbone,1,cleanedt1w,cleaned,Cpicture);                
%This creates a movie of the concentration map slices 
total=sum(sum(sum(C)))*.3*.3*2/1000000;                          %This calculates the total 
mmols of contrast in the image and displays it in the command window 
disp('The total amount of mmols in image= ') 
disp(total) 
volumedrug=sum(sum(sum(maskdrugreduced)))*.3*.3*2;   %Finds the total amount of 
volume of tissue with contrast above some minimum (below the threshold) level. 
disp('The total volume of contrast in mm3= ') 
disp(volumedrug) 
volumecement=sum(sum(sum(Cement)))*.3*.3*2;               %Finds the total amount of 
volume of tissue with contrast above some minimum level. 
disp('The total volume of cement in mm3= ') 
disp(volumecement) 
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A.8 Restack 
function [maskimport]=restack(filename, originalimaget1w) 
%this function is meant to import a stack of bmp images from mimics, find 
%the segmented mask region, and export a binary matrix of the mask.  The 
%mask must be in color (not black and white).  To import the mask put the 
%mask images in the directory folder.  The images before 10 must have a 0 
%removed before the unique number.   
[x,y,z]=size(originalimaget1w); 
[filteredlineart1w]=medianfilter(originalimaget1w,9);          %Runs the noise reducing 
filtering program medianfilter on the T1 weighted.  This is meant to prepare this image 
for transform into a mask. 
[mask]=masking(filteredlineart1w);                                       %This runs the program 
masking that creates a binary mask on the legs.  1's indicate that it is a point inside the 
legs, 0's indicate it is a point outside the legs. 
mask(206:256,230:256,:)=0;                                                  %This removes the red 
labels. 
mask(231:256,1:25,:)=0;   
imageimport=uint8(zeros(x,y,3,z));                                       %If this in not turned into a 
uint8 the images import binary and black/white 
for k=0:(z-1) 
   filenamemask = sprintf('%s%d-000.bmp',filename,k*2);   %Must be in same folder as 
the m files. 
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   imageimport(:,:,:,k+1) = imread(filenamemask);                %Reads in image files and 
stacks them into 3D matrix 
end 
maskimport=zeros(x,y,z);  
for k=1:z 
    for i=1:x 
        for j=1:y 
            if imageimport(i,j,1,k)==imageimport(i,j,2,k) && 
imageimport(i,j,1,k)==imageimport(i,j,3,k)                           %This makes anything that is 
greyscale a value of 0. 
                maskimport(i,j,k)=0; 
            else 
                maskimport(i,j,k)=1;                                               %This makes anything of 
any color a value of 1. 
            end 
        end 
    end 
  maskimport(:,:,k)=rot90(maskimport(:,:,k)); 
end 
maskimport=maskimport.*mask;                                           %This removes the right and 
left labels from the images. 
 
A.9 Reducemask 
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function [newmask]=reducemask(mask,diskradius) 
%This program reads in a binary mask image and reduces its size by a value 
%specified by the disk radius. 
if nargin==1 
    diskradius=4;                                                                      %If a diskradius is not 
specified use a value of 4 
end  
[x,y,z]=size(mask); 
SE=strel('disk',diskradius);                                                     %Creates a structural 
element with a disk shape and a radius specified by diskradius 
newmask=zeros(x,y,z); 
for k=1:z 
    newmask(:,:,k)=imerode(mask(:,:,k),SE);                          %Reduces the size of a mask 
in each slice. 
end 
 
A.10 Concentration 
function 
[Cpicture,C,Cement]=concentration(maskdrug,imageforbackground,cleaned,cleanedt1w,
T10estimate) 
%This program calculates a concentration map and a concentration map picture  
%from a segmented mask.  Imageforbackground can be either a T1 map (0) or a 
%T1 weighted image(1) 
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[x y z]=size(maskdrug); 
R=.00381;                                                                               %The relaxivity for Gd-
DTPA in mmol-1*ms-1 
C=zeros(x,y,z); 
[T1]=maskdrug.*cleaned;                                                      %This turns the binary 
segmentation to a segmentation that has the T1 values. 
[T10]=zeros(x,y,z); 
T10=(T10+1)*T10estimate;                                                   %Creates a matrix entirely of 
the value T10estimate. 
T10=axials; 
Cement=zeros(x,y,z);  
for k=1:z 
    for j=1:y 
        for i=1:x 
            if T1(i,j,k)~=0 && T10(i,j,k)~=0                               %Uses the equation bellow 
when the segmented region does not equal 0 
            C(i,j,k) = (1/R)*(1/T1(i,j,k) - 1/T10(i,j,k));                %This equation translates the 
T1 values to concentrations. 
            elseif T1(i,j,k)==0 && T10(i,j,k)~=0                         %Uses the bellow condition 
if the segmented region equals 0. 
            Cement(i,j,k)=1;     
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            elseif T1(i,j,k)~=0 && T10(i,j,k)==0                         %If the segmented region 
has a T1 value of 0 the signal is saturated or there is bone cement (something with no 
water) present. 
            C(i,j,k)=0; 
            else 
                C(i,j,k)=0; 
            end 
        end 
    end 
end   
cleanedadj=cleaned./7000;                                                     %This adjusts the scale to 1 
so that the Cpicture images plot well. 
[cleanedadj]=cutoff(cleanedadj,1);                                        %This cuts off any value 
above 1 (or above 7000 in the T1 map). 
cleanedadjt1w=cleanedt1w./1700000;                                   %This adjusts the T1 
weighted image scale to 1. 
cleanedadjt1w=cutoff(cleanedadjt1w,1); 
C=cutoff(C,5);                                                                        %This cuts off any value 
above 5 mM 
Cind=zeros(x,y,z); 
Cpicture=zeros(x,y,3,z); 
if imageforbackground==0                                                     %This loop is for making 
concentration map pictures with a t1 map as the background 
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for k=1:z 
    Cind(:,:,k)=gray2ind(C(:,:,k));                                            %This makes C and indexed 
matrix, instead of a grayscale 
    map=colormap(jet); 
    Cpicture(:,:,:,k)=ind2rgb(Cind(:,:,k),map);                        %This switches C from 
indexed to rgb. 
    for i=1:x 
        for j=1:y 
            if Cement(i,j,k)==1 
                Cpicture(i,j,:,k)=[0.56 0 0];                                    %Change this to change color 
of cement. If it is [0.56 0 0} cement it will plot red, like the top concentration. 
            elseif maskdrug(i,j,k)==0 
                Cpicture(i,j,:,k)=cleanedadj(i,j,k);                          %If there is no contrast plot 
the t1 map. 
            end 
        end 
    end 
end 
end 
if imageforbackground==1                                                     %This loop is for making 
concentration map pictures with a t1 weighted image as the background 
for k=1:z 
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    Cind(:,:,k)=gray2ind(C(:,:,k));                                            %This makes C and indexed 
matrix, instead of a grayscale 
    map=colormap(jet); 
    Cpicture(:,:,:,k)=ind2rgb(Cind(:,:,k),map);                         %This switches C from 
indexed to rgb. 
    for i=1:x 
        for j=1:y 
            if Cement(i,j,k)==1 
                Cpicture(i,j,:,k)=[0.56 0 0];%                                 %Change this to change 
color of cement. If it is [0.56 0 0} cement it will plot red, like the top concentration. 
            elseif maskdrug(i,j,k)==0 
            Cpicture(i,j,:,k)=cleanedadjt1w(i,j,k);                        %If there is no contrast plot 
the t1 weighted image. 
            end 
        end 
    end 
end 
end 
 
A.11 Movierabbitconcentration 
function 
[M]=movierabbitconcentration(maskdrug,maskbone,movietype,cleanedt1w,cleaned,Cpict
ure) 
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% This function will take a 3d image and make a movie of the view from the 
% bottom to the top of the stack.  First you must import maskdrug and 
% maskbone for that image set. Movietype is either a T1 map (0) or a 
% T1 weighted image(1) as the background.  You can either import a t1 map,  
% t1 weighted image, and concentration map picture or you will be prompted  
% to import the map and weighted image and a concentration map picture can be 
% created. 
[x,y,z]=size(maskdrug); 
startmovie=1;                                                                          %To cut down slices enter 
other values here. 
endmovie=z; 
  
xcut=1:x;                                                                                 %To zoom in on the area of 
interest enter other values here. 
ycut=1:y; 
% % % If running as a program not a function comment out this if loop. 
if nargin==3                                                                            %If you don't include a T1 
map and T1 weighted image it will prompt you to enter those here.  Then it will clean 
those up and below it will make the concentration map. 
originalimage=readdata3d;                                                     %GUI for importing HDR 
(and other) files.  This requires downloading the readdata3d function files from the 
matlab website.  First import a T1 map. 
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originalimaget1w=readdata3d;                                               %Then import a T1 weighted 
image                               
originalimage=originalimage(:,:,3:5:(end-2));                       %This indexes out the extra 
slices containing standard deviation, etc. and leaves only the actual map slices. 
[x y z]=size(originalimage);                                                   %Finds the dimensions of the 
T1 map after removing extra slices. 
originalimaget1w=originalimaget1w(:,:,1:z);                         %The T1 weighted hdr 
comes as a series of T1 weighted scans with different B values.  This takes only the set 
from the first B value.  This should match the dimensions of the T1 map. 
[filteredlinear]=medianfilter(originalimage,5);                      %Runs the noise removing 
filtering program medianfilter on the T1 map. 
[filteredlineart1w]=medianfilter(originalimaget1w,9);          %Runs the noise removing 
filtering program medianfilter on the T1 weighted.  This is meant to prepare this image 
for transform into a mask. 
[mask]=masking(filteredlineart1w);                                       %This runs the program 
masking that creates a binary mask on the legs.  1's indicate that it is a point inside the 
legs, 0's indicate it is a point outside the legs. 
cleaned=double(filteredlinear.*mask);                                   %multiplying the reduced 
noise T1 map by the binary mask removes all noise outside the legs. 
cleanedt1w=double(originalimaget1w.*mask); 
end 
maskbonep=permute(maskbone,[3 2 1]);                               %In order for the 3D image 
to pop up in the correct direction you have to switch axis. 
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maskdrugp=permute(maskdrug,[3 2 1]); 
X=0:(x-1);                                                                               %These are the axis for the 
3D image.  They must have the same size as the matrix. 
Y=0:(y-1); 
Z=0:(z-1);  
line=zeros(z,y,x); 
k=startmovie:endmovie; 
[x1 y1]=size(k); 
M=moviein(y1);                                                                     %This creates a matrix of the 
correct movie form to put frames in.  To make the movie slower increase this length and 
fill multiple slices with the same frame.  Keep in mind that a longer movie is a larger file.   
counter=1; 
if nargin==5 
   [Cpicture,C,Cement]=concentration(maskdrug,movietype,cleaned,originalimaget1w);  
%This makes a concentration map if one is not entered 
end 
for k=startmovie:endmovie 
close all 
line=zeros(z,y,x); 
line(k,ycut,30:240)=1;                                                            %This is a line (actually a 
plane) that moves up the 3D image in the plot to show what slice your on. 
h=figure;                                                                                 %This creates a handle for 
the figure that is used when you want to retrieve the frame later. 
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subplot(2,2,3)                                                                         %This is a plot of the 
concentration map. 
imshow(Cpicture(xcut,ycut,:,k),[0 1]);                                     
title('Concentration Map')  
subplot(2,2,1)                                                                          %This is a plot of the 3D 
masks 
hold on 
l=patch(isosurface(Y,Z,X,maskdrugp,.5)); 
set(l,'FaceColor','blue','EdgeColor','blue'); 
q = patch(isosurface(Y,Z,X,maskbonep,.3)); 
set(q,'FaceColor','red','EdgeColor','red'); 
  
t = patch(isosurface(Y,Z,X,line,.8)); 
set(t,'FaceColor','black','EdgeColor','black'); 
axis([1 250 1 42 1 250])                                                         %This holds the axis on the 
3d image so it doesn't stretch undesirably.  Here the form is [bottom up back] 
hold off 
title('3-D Drug Mask') 
subplot(2,2,2)                                                                          %This is a plot of the cleaned 
T1 map. 
imshow(cleaned(xcut,ycut,k),[0 5500]) 
title('T1 Map') 
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subplot(2,2,4)                                                                          %This is a plot of the cleaned 
T1 weighted image 
imshow(cleanedt1w(xcut,ycut,k),[0 1700000]) 
title('T1 Weighted Image') 
M(counter)=getframe(h);                                                        %This grabs the current plot 
and makes it a frame in the movie file.  It is important not to open other windows on top 
of the plot because this function is screen capturing the plot area and will capture 
whatever the top image is in that area. 
counter=counter+1; 
end 
movie2avi(M,'movieconcentration.avi');                                %This exports the movie as 
an avi to your directory folder 
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APPENDIX B  
PROTOCOL FOR IMAGE PROCESSING USING MATLAB AND MIMICS   
  167 
1. Run the program UnstacktifT1wandT1.m (which runs a median filter, masks, and 
exports a stack of TIFF files). 
2. Run the program T10estimatorwithimport.m to obtain the mean symmetrical histogram 
value and the standard deviation of the histogram. 
3. Sign on to the computer with mimics in Dr. Frakes' lab. 
4. Transfer the TIFF images from the directory to the computer with mimics using flash. 
5. Open Mimics x64 14.12. 
6. Go to File--> "new project wizard" to import pictures into mimics. 
7. Use the file browser in import wizard to find your file (mine shows up as Computer--
>Removable Disk K:). 
8. Highlight the folder that has all your images in it and click next. Open the T1 map 
images first. 
9. On the "image properties" page, change "Sorting order" to "numeric ascending", 
change the scan resolution to be the dimensions of one pixel (0.3x0.3x2 mm). 
10. On "Edit images" do not change anything just click next. 
11. In "check orientation" click the red letters to change the orientation, then click ok. 
This should take you out of the wizard. 
Tips on program: In quadrant 4 when the cursor is a + you can scroll to change the slice 
you are on.  You can also scroll when you select any of the other windows. 
12. Create a new mask with a threshold of 0 to T10estimate-standard deviation.  
13. Duplicate the first mask.  
14. Use the slice editor  to delete portion of contrast from the first mask. It is easiest and 
most reproducible to delete all parts of the mask within the muscle and bone. 
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15. Use the Boolean operator to subtract the first mask from the duplicate second mask. 
This should leave just the portions erased. 
16. Use the "region grow" function to select all pixels interconnected with the cement 
from the mask in step 15. 
17. Create a 3D object of the mask and export as an STL file. Also export the image 
slices of the mask as bmp images. 
18. Use the "new project wizard" to import the TIFF files of the T1 weighted image. 
19. Create a new mask with a threshold from 0 to 0. 
20. Duplicate the mask in 19. 
21. Use the slice editor with the livewire function to draw around the outside of the femur 
or inside of femur. 
22. Use Boolean operators to obtain the either the Cortex of the femur or intramedullary 
canal. 
23. Create a new mask with a threshold that includes everything except 0, then use the 
slice editor to draw or erase sections to obtain a clear outline of the legs. 
24. Create 3D objects of the legs and femurs. 
25. Import the STL file of the contrast agent. 
26. Plot the femurs, legs, and contrast agents in the 3D plot section. Go to file-
>screenshot to obtain images of the 3D plot. 
27. Import the mask file images into MATLAB using the mimicsimportandmapmaker.m 
program to obtain concentration maps. 
 
